



# A baseline survey of antimicrobial resistance in bacteria from selected New Zealand foods, 2009–2010

MAF Technical Paper No: 2011/53

Helen Heffernan<sup>1</sup>, Teck Lok Wong<sup>2</sup>,  
Jennifer Lindsay<sup>2</sup>, Barbara Bowen<sup>1</sup> and Rosemary Woodhouse<sup>1</sup>

<sup>1</sup> Antibiotic Reference Laboratory,  
Institute of Environmental Science and Research,  
P O Box 50348,  
Porirua

and

<sup>2</sup> Food Safety Group,  
Institute of Environmental Science and Research,  
P O Box 29181,  
Christchurch

ISBN 978-0-478-38440-6 (online)  
ISSN 2230-2794 (online)

27 April 2011



Ministry of Agriculture and Forestry  
Te Manatū Ahuwhenua, Ngāherehere



## Disclaimer

This report or document (“the Report”) is given by the Institute of Environmental Science and Research Limited (“ESR”) solely for the benefit of the New Zealand Food Safety Authority (now part of the Ministry of Agriculture and Forestry) and other Third Party Beneficiaries as defined in the Contract between ESR and the New Zealand Food Safety Authority, and is strictly subject to the conditions laid out in that Contract.

Neither ESR nor any of its employees makes any warranty, express or implied, or assumes any legal liability or responsibility for use of the Report or its contents by any other person or organisation.

Requests for further copies should be directed to:

Publication Adviser  
MAF Information Bureau  
P O Box 2526  
WELLINGTON

Telephone: 0800 00 83 33  
Facsimile: 04-894 0300

This publication is also available on the MAF website at [www.foodsafety.govt.nz/elibrary](http://www.foodsafety.govt.nz/elibrary)

© Crown Copyright, May 2011 - Ministry of Agriculture and Forestry

## Acknowledgments

The authors would like to thank:


- Dr Stephen On for his support, encouragement and scientific advice.
- The technical staff of the LAS-approved laboratories that provided samples from the National Microbiological Database Programme for this survey.
- The staff of the Public Health Laboratory, ESR Christchurch, for isolation and identification of the target bacterial species.
- Professor Mary Barton, Division of Health Sciences, University of South Australia, for peer review of this report.

**A baseline survey of  
antimicrobial resistance in bacteria  
in selected New Zealand foods,  
2009-2010**

Prepared for the New Zealand Food Safety Authority  
under Agreement for Services 11451  
Antimicrobial Resistance Surveillance -  
baseline survey in selected New Zealand foods



Dr Virginia Hope  
Science Programme Manager



Helen Heffernan

Barton  
Senior Scientist  
ESR

Project Leader

Professor of Microbiology  
University of South Australia

Peer Reviewer

Mary

---

<b>Summary</b>	<b>1</b>
<b>1 Introduction</b>	<b>3</b>
<b>2 Methods</b>	<b>4</b>
2.1 Source of bacterial isolates and samples for isolation of bacteria	4
2.2 Isolation and identification of <i>Campylobacter</i> , <i>E. coli</i> , <i>E. faecalis</i> and <i>E. faecium</i> from NMD programme samples	5
2.2.1 <i>Campylobacter</i>	5
2.2.2 <i>E. coli</i>	5
2.2.3 <i>E. faecalis</i> and <i>E. faecium</i>	5
2.3 Selection of isolates for antimicrobial susceptibility testing	6
2.3.1 <i>Campylobacter</i> , <i>E. coli</i> , <i>E. faecalis</i> and <i>E. faecium</i> from the NMD programme	6
2.3.2 <i>Salmonella</i> from the NMD programme	7
2.3.3 <i>E. coli</i> and <i>Salmonella</i> from the 2008-2009 Fresh Produce Survey	7
2.4 Antimicrobial susceptibility testing	7
2.4.1 Quality control	8
2.5 Data analysis	8
<b>3 Results</b>	<b>9</b>
3.1 Recovery of <i>Campylobacter</i> , <i>E. coli</i> and Enterococci isolates from NMD programme samples and numbers of isolates selected for antimicrobial susceptibility testing	9
3.2 <i>Campylobacter</i> antimicrobial susceptibility	10
3.3 <i>Salmonella</i> antimicrobial susceptibility	10
3.4 <i>Escherichia coli</i> antimicrobial susceptibility	11
3.5 <i>Enterococcus faecalis</i> and <i>E. faecium</i> antimicrobial susceptibility	12
<b>4 Discussion</b>	<b>14</b>
<b>5 References</b>	<b>19</b>
<b>Appendices</b>	<b>21</b>

Table 1. Number of NMD samples received, recovery of <i>Campylobacter</i> , <i>E. coli</i> and Enterococci isolates from NMD samples, and the numbers of isolates selected or available for antimicrobial susceptibility testing	9
Table 2. Resistance among <i>Campylobacter</i> from very young calves, pigs and poultry	10
Table 3. Resistance among <i>Escherichia coli</i> from very young calves, pigs, poultry and fresh produce	11
Table 4. Resistance among <i>Enterococcus faecalis</i> and <i>E. faecium</i> from very young calves, pigs and poultry	12
Table 5. Range of antimicrobials to be tested for each bacterial group, as recommended by the NZFSA Working Group on Implementation of Antimicrobial Resistance Surveillance	21
Table 6. Sensititre plate formats	22
Table 7. Interpretation of minimum inhibitory concentrations	25
Table 8. Isolation of <i>Campylobacter</i> from swabs of very young calf carcasses, pigs and poultry each quarter of the survey period	26
Table 9. Isolation of <i>Escherichia coli</i> from swabs of very young calf carcasses, pigs and poultry each quarter of the survey period	29
Table 10. Isolation of Enterococci from swabs of very young calf carcasses, pigs and poultry each quarter of the survey period	32
Table 11. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among <i>Campylobacter jejuni</i> isolated from very young calves (n=49) and poultry (n=295) <sup>1</sup>	35
Table 12. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among <i>Campylobacter coli</i> isolated from very young calves (n=7), pigs (n=10) and poultry (n=2)	36
Table 13. Resistance among <i>Campylobacter jejuni</i> from very young calves and poultry recovered from processing plants in the North Island versus the South Island <sup>1</sup>	37
Table 14. Resistance among <i>Campylobacter jejuni</i> from very young calves and poultry during each quarter of the survey period <sup>1,2,3</sup>	38
Table 15. Serotypes among <i>Salmonella</i> isolated from very young calves, pigs, poultry and fresh produce	39
Table 16. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among <i>Salmonella</i> isolated from very young calves (n=19), pigs (n=6), poultry (n=3) and fresh produce (n=2)	40
Table 17. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among <i>Escherichia coli</i> isolated from very young calves (n=300), pigs (n=303), poultry (n=306) and fresh produce (n=90)	43
Table 18. Resistance among <i>Escherichia coli</i> from very young calves, pigs and poultry recovered from processing plants in the North Island versus the South Island	46
Table 19. Resistance among <i>Escherichia coli</i> from very young calves, pigs and poultry during each quarter of the survey period <sup>1,2</sup>	47
Table 20. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among <i>Enterococcus faecalis</i> isolated from very young calves (n=185), pigs (n=228) and poultry (n=140)	48
Table 21. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among <i>Enterococcus faecium</i> isolated from very young calves (n=92), pigs (n=57) and poultry (n=158)	50

Table 22. Resistance among <i>Enterococcus faecalis</i> from very young calves, pigs and poultry recovered from processing plants in the North Island versus the South Island	52
Table 23. Resistance among <i>Enterococcus faecium</i> from very young calves, pigs and poultry recovered from processing plants in the North Island versus the South Island	53
Table 24. Resistance among <i>Enterococcus faecalis</i> from very young calves, pigs and poultry during each quarter of the survey period <sup>1,2</sup>	54
Table 25. Resistance among <i>Enterococcus faecium</i> from very young calves, pigs and poultry during each quarter of the survey period <sup>1,2</sup>	55
Table 26. Resistance among human isolates of <i>Campylobacter</i> , <i>Salmonella</i> , <i>Escherichia coli</i> , <i>Enterococcus faecalis</i> and <i>E. faecium</i> , 2009 <sup>1</sup>	56

## List of Figures

Page

Figure 1. Comparison of resistance among <i>Escherichia coli</i> from very young calves, pigs, poultry, 2009-2010, and urinary isolates from humans, 2009 <sup>1</sup>	57
Figure 2. Comparison of resistance among <i>E. faecalis</i> from very young calves, pigs, poultry, 2009-2010, with <i>E. faecalis</i> and <i>E. faecium</i> isolates from humans, 2009 <sup>1</sup>	58

## Summary

There is a lack of published data on antimicrobial resistance among bacteria associated with livestock in New Zealand. Comprehensive and current information on resistance among these bacteria is required to guide policy decisions on the use of antimicrobials in animal husbandry in this country. Therefore in 2005, the New Zealand Food Safety Authority's (NZFSA's) Expert Panel on Antibiotic Resistance recommended a programme of surveillance and monitoring of antimicrobial resistance among animal bacteria should be implemented as soon as practicable. A later Working Group developed the methodology for a baseline survey of antimicrobial resistance which was undertaken in 2009-2010 in accordance with the Working Group's recommended methods and scope. The results of this survey are presented in this report.

*Campylobacter* and *Salmonella*, representative of pathogenic bacteria, and *Escherichia coli* and Enterococci (*Enterococcus faecalis* and *E. faecium*), representative of commensal bacteria, were included in the survey. The isolates were sourced, in various ways, from specimens routinely collected from freshly dressed carcasses of very young calves, pigs and broiler poultry as part of the National Microbiological Database (NMD) programme. Isolates from NMD programme specimens taken between 5 October 2009 and 3 October 2010 were included in the survey. In addition, *Salmonella* (n=2) and *E. coli* (n=90) isolated during a Fresh Produce Survey conducted in 2008-2009 were included.

Antimicrobial susceptibility testing was performed by microbroth dilution (MBD) using the methods of the Clinical and Laboratory Standards Institute and commercially prepared MBD plates. The aim was to test the antimicrobial susceptibility of 300 isolates of each of the bacterial groups from each of the animal groups, and all isolates available from the Fresh Produce Survey. These targets were not met for all bacteria from all animal groups. During the 12-month survey period only 56 and 11 *Campylobacter* isolates were isolated from very young calves and pigs, respectively, and only 19, 6 and 3 *Salmonella* were isolated from calves, pigs and poultry, respectively.

Resistance was uncommon among *Campylobacter*. The majority (94.5%) of the *Campylobacter* isolates were *C. jejuni*. Among isolates of this species, 91.8% and 95.9% from very young calves and poultry, respectively, were susceptible to all antimicrobials tested. The only resistances identified among the *C. jejuni* isolates were ciprofloxacin/nalidixic acid resistance (2.7%) in poultry isolates, and streptomycin resistance in calf (8.2%) and poultry (1.0%) isolates. No *C. jejuni* were isolated from pigs.

In total only 30 *Salmonella* isolates were included in this survey. Two isolates from very young calves were resistant to streptomycin, and two isolates from pigs were sulphonamide resistant and one had additional resistance to trimethoprim.

*E. coli* from animals were more resistant than isolates from fresh produce. Ninety percent of *E. coli* from fresh produce were susceptible to all antimicrobials tested compared with 55.6% of isolates from poultry, 48.0% from very young calves and 35.0% from pigs. There was no resistance to cefotaxime, ciprofloxacin or gentamicin among *E. coli* from any of the animal groups or fresh produce. None of the isolates produced extended-spectrum or AmpC  $\beta$ -lactamase.

*continued*

Rates of ampicillin, chloramphenicol, neomycin, spectinomycin, streptomycin, sulphonamide and tetracycline resistance were relatively high among *E. coli* from some animals. Compared with isolates from the other sources, *E. coli* from very young calves were significantly ( $P \leq 0.05$ ) more resistant to ampicillin, neomycin and sulphonamides. *E. coli* from pigs were more resistant to chloramphenicol and spectinomycin, whereas poultry isolates were more resistant to nalidixic acid. Streptomycin and tetracycline resistance was higher in calf and pig isolates than those from poultry.

Among the *E. faecalis* isolates, 53.1% of those from pigs and 42.2% from very young calves were susceptible to all the antimicrobials tested (excluding quinupristin/dalfopristin to which *E. faecalis* is intrinsically resistant) compared with 17.9% of isolates from poultry. Among the *E. faecium* isolates, 31.6% of those from pigs were fully susceptible compared with 20.3% of isolates from poultry and 5.4% from calves. There was no resistance to ampicillin or vancomycin among *E. faecalis* or *E. faecium* from any of the animal groups.

Compared with *E. faecalis* from the other sources, isolates from very young calves were significantly more resistant to streptomycin, whereas isolates from pigs were more resistant to chloramphenicol and gentamicin, and isolates from poultry were more resistant to erythromycin and tetracycline. Compared with *E. faecium* from the other sources, isolates from calves were significantly more resistant to ciprofloxacin and tetracycline, whereas isolates from pigs were more resistant to streptomycin, and isolates from poultry were more resistant to nitrofurantoin. While the bacitracin MICs were not interpreted, the MICs for poultry isolates were high, with 95.0% of *E. faecalis* and 98.7% of *E. faecium* isolates having bacitracin MICs  $\geq 512$  mg/L.

There were some significant differences in rates of resistance among *E. coli* and Enterococci according to whether the animals they were isolated from were processed at plants in the North Island or the South Island. There were also some significant differences in resistance at different time periods during the 12 months of the survey.

The prevalence of resistance among bacteria from the food animals and fresh produce included in this survey was usually less than that reported for human isolates of the same bacterial species isolated in New Zealand in 2009, especially for the antibiotics of most importance in human medicine. Moreover, comparison of the results from this survey with the limited data available from earlier New Zealand studies on animal isolates does not suggest a trend of increasing resistance among bacteria from animals in New Zealand.

Finally, comparison of the results of this survey with 2009 data from the Danish DANMAP surveillance system, which uses similar methodology to that used in this survey but does not include an animal category of very young calves, showed that, with the exception of sulphonamide resistance in *E. coli* from poultry, resistance was either lower in pigs and poultry in New Zealand or not significantly different for the antibiotics that were commonly tested in both this survey and the DANMAP system. A similar comparison with 2008 data from the NARMS surveillance system in the United States for retail chicken breast and pork chop meat indicated that resistance was lower among bacteria from New Zealand poultry than American chicken breast meat, but higher among *E. faecalis* from New Zealand pigs than American pork chop meat.

# 1 Introduction

There is a lack of published data on the prevalence of antimicrobial resistance among bacteria associated with livestock in New Zealand. Comprehensive and current information on resistance among these bacteria is required to guide policy decisions on the use of antimicrobials in animal husbandry in this country. In 2005 the New Zealand Food Safety Authority's (NZFSA's) Expert Panel on Antibiotic Resistance recommended a programme of surveillance and monitoring of antimicrobial resistance among animal bacteria should be implemented as soon as practicable.<sup>1</sup> The Expert Panel's recommendation was subsequently endorsed by the Antimicrobial Resistance Steering Group.

The Expert Panel proposed that any surveillance programme be pragmatic and utilise existing sampling systems within the National Microbiological Database (NMD) programme. The NZFSA accepted the Expert Panel and Steering Group recommendations,<sup>2</sup> and, as part of the overall NZFSA Antimicrobial Resistance Implementation Project, established a Working Group, with external expert input, to develop, scope and recommend a surveillance programme. This Working Group recommended a baseline survey with the following components:

- The survey should focus on antimicrobial resistance among bacteria from food-producing animals.
- The bacteria of interest should be *Campylobacter*, *Salmonella*, *Escherichia coli*, *Enterococcus faecalis* and *Enterococcus faecium*.
- The food animals and locations to be surveyed should be very young calves (carcasses), culled dairy cattle (carcasses), pigs (carcasses) and broiler poultry (caeca and carcasses).
- The NMD programme should be utilised as the sampling framework, but additional isolation, identification and susceptibility testing of bacteria would be required.
- The baseline survey should cover all the bacteria of interest in all the identified food animal species.
- The panels of antimicrobials to be tested for each bacterial group should be those listed in Section 9 of the Working Group's report (see **Table 5** in the Appendix).
- ESR's current programme of antimicrobial resistance among *Salmonella* should be utilised and, if possible, expanded to include all *Salmonella* isolated as part of the NMD programme.
- An evaluation, utilising standard criteria for public health surveillance programmes, of the baseline survey should occur to inform decisions on future NZFSA surveillance of antimicrobial resistance.
- Isolates included in the baseline survey should be retained for future use.

The Institute of Environmental Science and Research (ESR) was contracted by the NZFSA to undertake the baseline survey in accordance with the Working Group's recommendations with a few notable changes:

- Bacteria from culled dairy cows were not to be included, as dairy and beef cows are not distinguished in the NMD programme.
- Bacteria from poultry caeca were not to be included as these samples are no longer available as part of the NMD programme.

In addition to the bacteria recovered from the NMD programme, *E. coli* and *Salmonella* isolated as part of a national Fresh Produce Survey conducted in 2008 and 2009 by ESR for the NZFSA were to be included in this baseline survey.<sup>3</sup>

## 2 Methods

### 2.1 SOURCE OF BACTERIAL ISOLATES AND SAMPLES FOR ISOLATION OF BACTERIA

The *Campylobacter*, *Salmonella*, *E. coli*, *E. faecalis* and *E. faecium* isolates included in the survey were from two sources:

#### 1 The National Microbiological Database (NMD) programme

Presumptive *Campylobacter* and *E. coli* isolates, and samples for the isolation of *Campylobacter*, *E. faecalis* and *E. faecium*, were obtained from the LAS-approved laboratories<sup>1</sup> that perform NMD programme testing for abattoirs processing very young calves and pigs and for plants processing broiler poultry. The samples used were rinsates of swabs of calf and pig carcasses and poultry whole carcass rinsates.

The laboratories were requested to refer a specified number of isolates or samples from each processing plant to ESR each week, fortnight or quarter over a 12-month period, 5 October 2009 to 3 October 2010. The 5 October 2009 start was chosen to coincide with the date that the NMD programme was extended to include pig processing. The collection period for isolates and samples from plants processing very young calves was confined to the months that these calves are being processed, that is, the ‘bobby calf’ season (5 October – 5 November 2009 and 7 July – 3 October 2010). The number of isolates and samples specified for each processing plant was proportional to the plant’s throughput.

*Salmonella* isolated as part of the NMD programme from very young calves, pigs and poultry during the 12-month survey period were identified from the NMD database. These *Salmonella* isolates were obtained from ESR’s Enteric Reference Laboratory, as all *Salmonella* isolated as part of the NMD programme are referred to this laboratory. For the survey, the NMD database was upgraded to include the ESR laboratory numbers for the *Salmonella* isolates. This upgrade facilitated the identification and retrieval of the *Salmonella* isolates that were to be included in the survey.

#### 2 The 2008-2009 Fresh Produce Survey

All *E. coli* and *Salmonella* isolated during the 2008-2009 Fresh Produce Survey and that had been stored were obtained from the ESR laboratory which conducted the survey. The isolates had been stored at -80°C in cryogenic media.

---

<sup>1</sup> The Laboratory Approval Scheme (LAS) is an integral part of NZFSA official assurances for market access. The LAS is designed specifically to encompass laboratory requirements for regulatory samples for New Zealand official assurances. LAS-approved laboratories that carry out microbiological and chemical or any other specified laboratory testing for market access assurances must follow standards and requirements specified by LAS.

## 2.2 ISOLATION AND IDENTIFICATION OF *CAMPYLOBACTER*, *E. COLI*, *E. FAECALIS* AND *E. FAECIUM* FROM NMD PROGRAMME SAMPLES

The NMD programme protocols specify that only *Salmonella* are definitively identified. In addition the protocols specify that *Campylobacter* isolated from poultry are confirmed as *Campylobacter* species by oxidase and latex agglutination (Microgen Bioproducts Ltd, Camberley, Surrey, UK) tests, and that *E. coli* are presumptively identified on the basis of characteristic growth on *E. coli* petrifilms. Therefore, for this survey, additional work was required to isolate *Campylobacter* from very young calves and pigs, to speciate all *Campylobacter* isolates, to purify and confirm presumptive *E. coli* isolates, and to isolate and identify *E. faecalis* and *E. faecium*. This isolation and identification work was undertaken by ESR's Food Group at the Christchurch Science Centre using the following methods.

### 2.2.1 *Campylobacter*

To obtain *Campylobacter* from very young calves and pigs, 2 mL of carcass swab rinsate was added to 18 mL of Bolton broth (Lab M, Bury, Lancashire, UK) in the LAS-approved laboratory. The Bolton broths were kept chilled and transported to ESR in an insulated container. At ESR, the broths were incubated in a microaerobic environment (provided in a dedicated microaerobic incubator) at 37°C for at least 4 hours to resuscitate any *Campylobacter* present, followed by further incubation at 42°C microaerobically for 44 hours. A loopful (10 µL) of the broth culture was streaked on modified charcoal cefoperazone desoxycholate agar (mCCDA, Lab M) and incubated at 42°C microaerobically for 48 hours to obtain single colonies.

To obtain *Campylobacter* from poultry, *Campylobacter* species from whole carcass rinsates isolated on mCCDA plates in LAS-approved laboratories were picked onto Amies charcoal swabs (one swab per positive carcass). These swabs were transported chilled to ESR. At ESR, culture from each swab was streaked on mCCDA and incubated at 42°C microaerobically for 48 hours to obtain single colonies.

Typical *Campylobacter*-like colonies on mCCDA were purified by culturing on sheep blood agar (Columbia Blood Agar base by Difco, Becton Dickinson, Sparks, MD, USA) at 42°C microaerobically for 48 hours, and then tested for oxidase and, if positive, definitively identified and speciated by PCR.<sup>4</sup> All speciated isolates were stored at -80°C in cryogenic media until subcultured for susceptibility testing.

### 2.2.2 *E. coli*

To obtain *E. coli* from very young calves, pigs and poultry, the LAS-approved laboratories submitted the *E. coli* Petrifilms that had been used to enumerate *E. coli* in calf and pig carcass swab rinsates and poultry whole carcass rinsates. The Petrifilms were transported chilled to ESR. At ESR, blue colonies typical of *E. coli* were picked and streaked on eosin methylene blue agar (EMB, Merck, Darmstadt, Germany) and tested for indole production in tryptone broth (Becton Dickinson).<sup>5</sup> Colonies which were indole positive and produced a characteristic metallic sheen on EMB agar were purified on sheep blood agar and stored at -80°C in cryogenic media until subcultured for susceptibility testing.

### 2.2.3 *E. faecalis* and *E. faecium*

To obtain *E. faecalis* and *E. faecium* from very young calves, pigs and poultry, the LAS-approved laboratories submitted calf and pig carcass swab rinsates and poultry whole carcass rinsates. The rinsates were transported chilled to ESR. At ESR, 2 mL of each rinsate was

added to 18 mL of azide dextrose broth (Oxoid, Basingstoke, England) and incubated at 35°C for 18-24 hours. The broths were streaked on Slanetz & Bartley agar (Oxoid) and incubated at 44°C for 48 hours. Reddish-pink to reddish-brown colonies were picked and purified on sheep blood agar. Colonies were confirmed as *Enterococcus* by testing for growth in brain heart infusion broth (Becton Dickinson) at 45°C and in 6.5% salt broth at 35°C for 48 hours. *Enterococcus* isolates were speciated by PCR.<sup>6</sup> All *E. faecalis* and *E. faecium* isolates were stored at -80°C in cryogenic media until subcultured for susceptibility testing.

## 2.3 SELECTION OF ISOLATES FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING

### 2.3.1 *Campylobacter*, *E. coli*, *E. faecalis* and *E. faecium* from the NMD programme

For operational purposes and to achieve even sampling over the 12-month survey period, the 12 months were divided into four quarterly periods: 5 October-31 December 2009, 1 January-31 March 2010, 1 April-30 June 2010 and 1 July-3 October 2010. The aim was to select for antimicrobial susceptibility testing a total of 300 isolates, 75 per quarter, of each bacterial group (ie, *Campylobacter*, *E. coli* and Enterococci) from each animal group (ie, very young calves, pigs and poultry). When selecting Enterococci, equal numbers of *E. faecalis* and *E. faecium* were selected, where available.

Individual target numbers of isolates were set for each processing plant and were proportional to the plant's historical throughput. Except for isolates from very young calves, isolates were selected for susceptibility testing with the aim of obtaining the quarterly target number of isolates of each bacterial group from each processing plant. When the number of isolates recovered from samples from a plant was less than the target number, the shortfall was made up by selecting a greater number of isolates from that plant in another quarter. If there were insufficient isolates from a plant to do this, then, at the end of the survey when all samples had been processed, any remaining shortfalls in isolate numbers was made up by selecting isolates from other plants with the aim of achieving the quarterly target totals of 75 isolates.

Due to the limited 'bobby calf' season, isolates from very young calves were only available from some (South Island) processing plants in the 5 October-31 December 2009 quarter and all plants in the 1 July-3 October 2010 quarter. For those plants still processing in the 5 October-31 December 2009, isolates were selected for susceptibility testing with the aim of obtaining about one-third of the total number of isolates required from these plants. This strategy was based on the assumption that approximately one-third of these plants' annual processing occurred during this quarter. The balance for these plants and the total numbers required from the other plants were selected from isolates recovered in the 1 July-3 October 2010 quarter.

### 2.3.2 *Salmonella* from the NMD programme

All *Salmonella* isolated from very young calves (n=19), pigs (n=9) and poultry (n=3) as part of the NMD programme during the 12-month survey period were included for susceptibility testing.

### 2.3.3 *E. coli* and *Salmonella* from the 2008-2009 Fresh Produce Survey

All available *E. coli* (n=90) and *Salmonella* (n=2) isolated during the 2008-2009 Fresh Produce Survey were included for susceptibility testing.

## 2.4 ANTIMICROBIAL SUSCEPTIBILITY TESTING

The antimicrobial susceptibility testing was undertaken by ESR's Antibiotic Reference Laboratory at the Kenepuru Science Centre.

All susceptibility testing was performed by broth microdilution using Sensititre plates (Trek Diagnostic Systems, East Grinstead, England). Three plate types were used: one for *Campylobacter* (code EUCAMP), one for *E. coli* and *Salmonella* (code NZFSAN), one for Enterococci (code NZFSAP). The plate for *Campylobacter* was standard, however, the *E. coli/Salmonella* plate and Enterococci plate were customised for this survey. The antibiotics included in each plate, the concentration ranges and plate configurations are detailed in Table 6 in the Appendix.

The inoculum preparation, inoculum standardisation, incubation conditions, and determination of minimum inhibitory concentration (MIC) end points, were according to the Clinical and Laboratory Standard Institute's (CLSI's) microbroth dilution method.<sup>7</sup> The MICs were interpreted using the CLSI interpretive standards for human isolates.<sup>8,9</sup> For veterinary-specific antibiotics, the MICs were interpreted using the CLSI standards for bacteria isolated from animals.<sup>10</sup> Where none of the CLSI standards contained interpretive standards for a particular antibiotic, the epidemiological cut-off values used in the DANMAP surveillance system were applied.<sup>11</sup> The interpretive standards used are summarised in Table 7 in the Appendix. Neither CLSI nor DANMAP have bacitracin or tylosin interpretive standards for Enterococci. Therefore the MICs of these antibiotics were not interpreted.

*E. coli* and *Salmonella* that screened positive for extended spectrum  $\beta$ -lactamases (ESBLs) by growing at a concentration of 1 mg/L cefotaxime and/or 1 mg/L ceftazidime were further tested by the CLSI ESBL disc confirmatory method to confirm the presence of an ESBL.<sup>8</sup> Cefoxitin-resistant *E. coli* and *Salmonella* were screened for AmpC  $\beta$ -lactamase with a boronic acid double-disc synergy test.<sup>12</sup> Any screen-positive isolates were tested by PCR for plasmid-mediated AmpC  $\beta$ -lactamase.<sup>13</sup>

Vancomycin-resistant or intermediate Enterococci were further tested by PCR to confirm the presence of the *vanA* or *vanB* gene.<sup>14</sup>

### 2.4.1 Quality control

All susceptibility testing was fully controlled according to the CLSI protocols and the prescribed quality control strains were used:

- *E. coli* ATCC 25922
- *E. coli* ATCC 35218
- *Enterococcus faecalis* ATCC 29212
- *Enterococcus faecalis* ATCC 51299
- *Campylobacter jejuni* ATCC 33560

The quality control testing included the prerequisite 30 consecutive days' testing of each of the three types of Sensititre plates. Each lot of Sensititre plates was controlled by one day of testing. During routine testing, quality control strains were run weekly.

The divalent cation content of all lots of Mueller-Hinton broth (Difco) used was adjusted, if necessary, and then tested for satisfactory performance as specified in the CLSI standards.<sup>7</sup> Each lot of Mueller-Hinton broth was also tested for acceptable thymidine and thymine content, that is, suitability for trimethoprim and sulphonamide susceptibility testing, as specified in the CLSI standards.<sup>7</sup>

## 2.5 DATA ANALYSIS

Statistical analyses were performed with SAS software v.9.1.3 (SAS Institute Inc, Cary, NC, USA). The chi-square test or Fisher's exact test, as appropriate, were used to determine the significance of any observed differences. Chi-square for trend was used to determine the significance of any changes over the four quarters of the survey period. An associated P value  $\leq 0.05$  was used to identify whether a difference or trend was significant.

The comparison of resistance among bacteria isolated in the North Island with those isolated in the South Island was confined to isolates from the NMD programme as the geographic origin of the fresh produce isolates was not available.

The analysis of full susceptibility among Enterococci excluded bacitracin and tylosin as the MICs of these antibiotics were not interpreted.

## 3 Results

### 3.1 RECOVERY OF *CAMPYLOBACTER*, *E. COLI* AND ENTEROCOCCI ISOLATES FROM NMD PROGRAMME SAMPLES AND NUMBERS OF ISOLATES SELECTED FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING

The numbers of NMD programme samples received for processing from each of the animal groups; the numbers of *Campylobacter*, *E. coli* and Enterococci recovered from these samples; and the numbers of *Campylobacter*, *Salmonella*, *E. coli*, and *E. faecalis* or *E. faecium* selected or available for antimicrobial susceptibility testing from isolates recovered and fully identified from the NMD programme and the Fresh Produce Survey are summarised in Table 1. This information is shown in more detail for individual processing plants on a quarterly basis in Table 8, Table 9 and Table 10 in the Appendix, respectively, for *Campylobacter*, *E. coli* and Enterococci from NMD programme samples.

Table 1. Number of NMD samples received, recovery of *Campylobacter*, *E. coli* and Enterococci isolates from NMD samples, and the numbers of isolates selected or available for antimicrobial susceptibility testing

	<i>Campylobacter</i> <sup>1</sup>	<i>Salmonella</i>	<i>E. coli</i>	Enterococci <sup>2</sup>
<b>Very young calves</b>				
Number of samples	1159	NA <sup>3</sup>	1028	1143
Number of isolates recovered	56	NA	547	576
Number selected/available for susceptibility testing	56	19	300	277
<b>Pigs</b>				
Number of samples	1661	NA	698	1636
Number of isolates recovered	11	NA	481	381
Number selected/available for susceptibility testing	11	6	303	285
<b>Poultry</b>				
Number of samples	445	NA	610	871
Number of isolates recovered	420	NA	501	627
Number selected/available for susceptibility testing	297	3	306	298
<b>Fresh produce</b>				
Number available for susceptibility testing	NA	2	90	NA

1 All *Campylobacter* recovered from very young calves and pigs were susceptibility tested.

2 Not all Enterococci recovered were speciated, but all those from very young calves and pigs that were speciated were susceptibility tested.

3 NA, not applicable

### 3.2 *CAMPYLOBACTER* ANTIMICROBIAL SUSCEPTIBILITY

The antimicrobial susceptibility of 56 *Campylobacter* isolates from very young calves, 11 isolates from pigs, and 297 isolates from poultry was tested (Table 1) and is reported in Table 2. The species distribution of the *Campylobacter* isolates is also given in Table 2. The full MIC distributions among *C. jejuni* and *C. coli* are shown in **Table 11** and **Table 12**, respectively, in the Appendix.

Table 2. Resistance among *Campylobacter* from very young calves, pigs and poultry

Antimicrobial	Percent resistance							
	<i>C. jejuni</i>			<i>C. coli</i>				<i>C. lari</i>
	Very young calves n=49	Poultry n=295	Total n=344	Very young calves n=7	Pigs n=10	Poultry n=2	Total n=19	Pigs n=1
Chloramphenicol	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Ciprofloxacin	0.0	2.7	2.3	0.0	0.0	0.0	0.0	100.0
Erythromycin	0.0	0.0	0.0	0.0	20.0	0.0	10.5	0.0
Gentamicin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Nalidixic acid	0.0	2.7	2.3	0.0	0.0	0.0	0.0	100.0
Streptomycin	8.2	1.0	2.0	0.0	20.0	0.0	10.5	0.0
Tetracycline	0.0	0.3	0.3	0.0	30.0	0.0	15.8	100.0

Resistance was uncommon among *Campylobacter*. Among the *C. jejuni* isolates, 91.8% and 95.9% of those from very young calves and poultry, respectively, were susceptible to all antimicrobials tested. The only significant difference in resistance among the *Campylobacter* from the different animal groups was higher streptomycin resistance among *C. jejuni* from calves compared with poultry. The small number of *C. coli* isolates precludes any meaningful comparison of resistance among this species in the different animal groups.

Ciprofloxacin and nalidixic acid resistance, which is conferred by the same mechanism, was significantly higher among *C. jejuni* from poultry processed in the South Island compared with that processed in the North Island (Table 13 in the Appendix). The ciprofloxacin/nalidixic acid-resistant isolates from poultry processed in the South Island were all isolated in the third and fourth quarters and accounted for the significantly higher rates of resistance to these two antibiotics in these quarters among poultry (Table 14 in the Appendix).

### 3.3 *SALMONELLA* ANTIMICROBIAL SUSCEPTIBILITY

There were only 30 *Salmonella* isolated during the survey period and from the Fresh Produce Survey: 19 isolates from very young calves, 6 from pigs, 3 from poultry and 2 from fresh produce. The serotypes of the isolates are shown in Table 15 in the Appendix.

The full MIC distributions are shown in Table 16 in the Appendix. All *Salmonella* were susceptible to all the antibiotics tested except for two isolates from calves and two from pigs. Both resistant isolates from calves were *S. Typhimurium* phage type 9 and both had mono-resistance to streptomycin. One of the resistant isolates from pigs was *S. Brandenburg* resistant to sulphamethoxazole and trimethoprim, and the other was *S. Derby* resistant to sulphamethoxazole.

### 3.4 *ESCHERICHIA COLI* ANTIMICROBIAL SUSCEPTIBILITY

The antimicrobial susceptibility of 300 *E. coli* isolates from very young calves, 303 isolates from pigs, 306 isolates from poultry, and 90 from fresh produce was tested (Table 1) and is reported in (Table 3). The full MIC distributions are shown in **Table 17** in the Appendix.

Table 3. Resistance among *Escherichia coli* from very young calves, pigs, poultry and fresh produce

Antimicrobial	Percent resistance				
	Very young calves n=300	Pigs n=303	Poultry n=306	Fresh produce n=90	Total n=999
Ampicillin	23.7	8.9	4.9	2.2	11.5
Apramycin	0.0	0.3	0.3	0.0	0.2
Cefotaxime	0.0	0.0	0.0	0.0	0.0
Cefoxitin	1.0	1.3	0.3	2.2	1.0
Ceftiofur	0.0	0.0	0.0	0.0	0.0
Cephalothin	4.0	2.0	2.0	2.2	2.6
Chloramphenicol	3.3	10.2	0.7	1.1	4.4
Ciprofloxacin	0.0	0.0	0.0	0.0	0.0
Co-amoxiclav	1.0	0.7	0.0	3.3	0.8
Gentamicin	0.0	0.0	0.0	0.0	0.0
Nalidixic acid	0.3	0.7	5.6	0.0	2.0
Neomycin	28.3	2.6	2.9	0.0	10.2
Spectinomycin	8.7	24.4	5.9	0.0	11.8
Streptomycin	44.3	32.3	10.1	1.1	26.3
Sulfamethoxazole	45.0	32.7	30.7	1.1	32.9
Tetracycline	40.7	48.5	12.1	6.7	31.2
Trimethoprim	12.7	8.3	6.7	1.1	8.5

There was no resistance to cefotaxime, ceftiofur, ciprofloxacin or gentamicin among *E. coli* from any of the animal groups or fresh produce. None of the isolates produced ESBL or AmpC  $\beta$ -lactamase. The rates of resistance to apramycin, cefoxitin, cephalothin, co-amoxiclav and nalidixic acid were relatively low among isolates from all animals groups and fresh produce.

*E. coli* from animals were more resistant than isolates from fresh produce. Ninety percent of *E. coli* from fresh produce were susceptible to all antimicrobials tested compared with 55.6% of isolates from poultry, 48.0% from calves and 35.0% from pigs. Compared with isolates from other sources, *E. coli* from calves were significantly more resistant to ampicillin, neomycin and sulphonamides. Isolates from pigs were more resistant to chloramphenicol and spectinomycin, whereas poultry isolates were more resistant to nalidixic acid. Streptomycin and tetracycline resistance was higher in calf and pig isolates than those from poultry and fresh produce.

There were some significant differences in rates of resistance among *E. coli* from pigs and poultry, but not very young calves, processed in the North Island compared with those processed in the South Island. Isolates from pigs processed in the North Island were more

resistant to chloramphenicol, spectinomycin, streptomycin and sulphonamides, but less resistant to tetracycline. Isolates from poultry processed in the South Island were more resistant to ceftiofur, spectinomycin, streptomycin and trimethoprim (**Table 18** in the Appendix)

There were also some significant differences in rates of resistance among *E. coli* from very young calves and pigs, but not poultry, in the different quarters of the survey period (Table 19).

### 3.5 *ENTEROCOCCUS FAECALIS* AND *E. FAECIUM* ANTIMICROBIAL SUSCEPTIBILITY

The antimicrobial susceptibility of 277 *E. faecalis* or *E. faecium* isolates from very young calves, 285 *E. faecalis* or *E. faecium* isolates from pigs, and 298 *E. faecalis* or *E. faecium* from poultry was tested (Table 1) and is reported in (Table 4). The full MIC distributions among each species are shown in Table 20 and Table 21 in the Appendix.

Table 4. Resistance among *Enterococcus faecalis* and *E. faecium* from very young calves, pigs and poultry

Antimicrobial	Percent resistance							
	<i>E. faecalis</i>				<i>E. faecium</i>			
	Very young calves n=185	Pigs n=228	Poultry n=140	Total n=553	Very young calves n=92	Pigs n=57	Poultry n=158	Total n=307
Ampicillin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chloramphenicol	3.8	8.3	0.0	4.7	0.0	1.8	0.6	0.7
Ciprofloxacin	1.6	0.9	0.7	1.1	79.4	33.3	45.6	53.4
Erythromycin	11.4	27.6	33.6	23.7	9.8	24.6	24.7	20.2
High-level Gentamicin	0.0	8.3	0.0	3.4	0.0	0.0	0.0	0.0
Nitrofurantoin	1.1	0.4	1.4	0.9	9.8	21.1	29.8	22.2
Quinupristin/dalfopristin	-	-	-	-	26.1	29.8	31.7	29.6
High-level Streptomycin	35.7	21.1	3.6	21.5	12.0	15.8	3.2	8.1
Tetracycline	54.6	43.0	77.9	55.7	62.0	38.6	35.4	44.0
Vancomycin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

There was no resistance to ampicillin or vancomycin among *E. faecalis* or *E. faecium* from any of the animal groups. Two isolates, both from pigs, had intermediate-vancomycin resistance (MIC 8 mg/L), but did not have either the *vanA* or *vanB* gene.

Among the *E. faecalis* isolates, 53.1% of those from pigs and 42.2% from very young calves were susceptible to all the antimicrobials tested (excluding quinupristin/dalfopristin to which *E. faecalis* is intrinsically resistant) compared with 17.9% of isolates from poultry. Among the *E. faecium* isolates, 31.6% of those from pigs were fully susceptible compared with 20.3% of isolates from poultry and 5.4% from calves.

Compared with *E. faecalis* from other sources, isolates from very young calves were significantly more resistant to streptomycin, whereas isolates from pigs were more resistant to chloramphenicol and gentamicin, and isolates from poultry were more resistant to erythromycin and tetracycline. Compared with *E. faecium* from other sources, isolates from calves were significantly more resistant to ciprofloxacin and tetracycline, whereas isolates from pigs were more resistant to streptomycin, and isolates from poultry were more resistant to nitrofurantoin. While the bacitracin MICs were not interpreted, the MICs for poultry isolates were higher than those for calf or pig isolates, with 95.0% of *E. faecalis* and 98.7% of *E. faecium* isolates having bacitracin MICs  $\geq 512$  mg/L (Table 20 and Table 21 in the Appendix).

There were some significant differences in rates of resistance among *E. faecalis* and *E. faecium* from animals processed in the North Island compared with those processed in the South Island. *E. faecalis* from very young calves processed in the South Island were more resistant to streptomycin, and isolates from pigs processed in the North Island were more resistant to gentamicin and less resistant to tetracycline (Table 22 in the Appendix). *E. faecium* from calves processed in the North Island were more resistant to quinupristin/dalfopristin; isolates from pigs processed in the South Island were more resistant to ciprofloxacin, erythromycin and tetracycline; and isolates from poultry in the South Island were more resistant to tetracycline (Table 23 in the Appendix).

There were also some significant differences in rates of resistance among *E. faecalis*, but not *E. faecium*, from very young calves and poultry in the different quarters of the survey period (Table 24 and Table 25 in the Appendix)

## 4 Discussion

The principal aim of this survey was to estimate the prevalence of resistance to important and commonly used antimicrobials among representative collections of pathogenic bacteria (*Campylobacter* and *Salmonella*) and indicator, commensal bacteria (*E. coli*, *E. faecalis* and *E. faecium*) isolated from freshly dressed carcasses of very young calves, pigs and broiler poultry in New Zealand abattoirs and processing plants over a 12-month period. This aim was extended to include resistance among *Salmonella* and *E. coli* isolated during the 2008-2009 Fresh Produce Survey.<sup>3</sup>

This is the first such survey undertaken in New Zealand and should provide baseline information to monitor any changes in resistance among bacteria from food-producing animals as well as provide current information to guide policy decisions on the use of antimicrobials in animal husbandry in this country. The three animal groups included in the survey, very young calves, pigs and broiler poultry, were chosen as there is a greater use of antimicrobials in the rearing of these animals than other food animals.

### *Resistance in relation to antibiotic use*

Data on the use of antimicrobials in animal rearing in this country is limited. The NZFSA monitors and reports on sales of antibiotics for use in animals, however, these reports do not provide information on the amounts of antibiotics sold specifically for use in the three animal species included in this survey.<sup>15</sup> However, some comments about known usage and the prevalence of resistance found in this survey can be made. Such comparisons are always complicated by cross resistance between antibiotics of the same or similar classes and also by linked resistance between antibiotics of different classes due, for example, to resistance determinants being carried on the same genetic element such as a plasmid.

Over the 2004-2009 period, zinc bacitracin accounted for 35-47%, by weight, of all antibiotic sales, and 71-80% of all antibiotics administered in feed and water. Almost all of this bacitracin is used in the broiler industry to control clostridial enteritis, and this use is reflected in the very high proportion ( $\geq 95\%$ ) of Enterococci from poultry in this survey that had high bacitracin MICs of  $\geq 512$  mg/L.

Penicillins, macrolides, sulphonamides/trimethoprim and tetracyclines account for the majority of the remaining antibiotic sales. Among food-producing animals the bulk of the penicillins are used in dairy cattle. Macrolides are used mainly in the pig industry, but erythromycin resistance was not more prevalent among isolates (Enterococci) from pigs than other animals. Sulphonamides are commonly used to treat scouring in calves, although the very young calves included in this survey are not usually treated. However, the highest rate of sulphonamide resistance was among *E. coli* isolated from very young calves, which may reflect the use of this antibiotic in other animals sharing the same environment. Tetracyclines are commonly used to control respiratory disease in pigs and tetracycline resistance in *E. coli* was most prevalent among isolates from pigs, but among Enterococci tetracycline resistance was most prevalent in *E. faecalis* from poultry.

### *Comparison of resistance with that found among human bacterial isolates*

There is international concern, and now some evidence, that the use of antimicrobials in animal rearing and other agricultural uses is contributing to the problem of antibiotic resistance among human pathogens. However, the results of this survey indicate that bacteria from food-producing animals in New Zealand, or at least those that the general public are

most likely to be exposed to via the food chain, are probably not a significant source of resistant human pathogens or a reservoir of resistance genes. Where there is comparable data, the prevalence of resistance among bacteria from the food animals and fresh produce included in this survey was usually less than that reported for human isolates of the same species isolated in New Zealand in 2009 (see Table 26, Figure 1 and Figure 2 in the Appendix).

Data on resistance among human *Campylobacter* isolates is limited, as it is not routinely tested in diagnostic laboratories. However, based on the data that is available for fluoroquinolone and erythromycin, resistance to each of these two antibiotics has varied between zero and 3% in recent years.<sup>16</sup> In this survey, similar levels of resistance to these two antibiotics were identified among the animal isolates of *C. jejuni*, with 2.3% ciprofloxacin resistance and no erythromycin resistance.

Due to the low numbers of *Salmonella* isolated from animal carcasses during the survey period and during the Fresh Produce Survey, it is difficult to make valid comparisons of the resistance found among this organism in this survey with other data. However, among human *Salmonella* isolates in New Zealand in 2009 some resistance was detected to most antibiotics tested (Table 26 in the Appendix) and ESBL- and AmpC  $\beta$ -lactamase- producing *Salmonella* were identified. Whereas only low levels of streptomycin, sulphonamide and trimethoprim resistance was detected among isolates included in this survey. Resistance among *Salmonella* from non-human sources, including animals, in New Zealand is routinely monitored by ESR and compared with resistance among human isolates. This monitoring has shown that almost invariably, where there is a difference in resistance, *Salmonella* from non-human sources are less resistant than those from human sources.<sup>17</sup>

The rates of resistance among the *E. coli* included in this survey were lower than those reported among *E. coli* from humans (see Figure 1 in the Appendix).<sup>16</sup> Rising rates of resistance to third-generation cephalosporins and fluoroquinolones among Gram-negative bacteria, such as *E. coli*, are a major concern in human medicine. Importantly no resistance was detected to either of these antimicrobials among the *E. coli* included in this survey. However, while no fluoroquinolone (ciprofloxacin) resistance was detected among *E. coli*, resistance to the earlier-generation quinolone, nalidixic acid, was detected, in particular among 5.6% of *E. coli* from poultry. This is of some concern as it is likely that these nalidixic acid-resistant isolates have the first of the two-step mutation that results in resistance to fluoroquinolones.<sup>18</sup>

The resistance data for *E. faecalis* and *E. faecium* available for human isolates and presented in Table 26 in the Appendix is combined for both species which makes it difficult to compare with the species-specific data collected in this survey.<sup>16</sup> There are usually significant differences in the antimicrobial susceptibility of *E. faecalis* and *E. faecium*. However, 90% of human enterococcal infections are usually due to *E. faecalis*, and therefore if the resistance among human isolates is compared with that among the animal *E. faecalis* included in this survey, once again it is notable that resistance was generally lower in the animal isolates (see Figure 2 in the Appendix). Importantly, no vancomycin resistance was detected among the animal Enterococci, but the rates of quinupristin/dalfopristin resistance detected in *E. faecium* were high, ranging from 26.1% to 31.7% across the animal groups.

The above comparisons of resistance among human isolates with that among the animal and fresh produce isolates included in this survey need to be interpreted with caution. The human isolate data is based on isolates recovered from diagnostic specimens. Rates of resistance among isolates from such specimens may be higher than those in the total bacterial population due to the recognised biases in such diagnostic specimens.<sup>19,20</sup> For example, a specimen may

only be taken from a patient following the failure of initial empirical treatment which is more likely if the causative organism is resistant.

#### *Comparison of resistance with that found in earlier studies of animal bacterial isolates*

While this survey was considered a baseline survey, there have been some earlier and smaller studies of antimicrobial resistance among bacteria from animals and foods in New Zealand. These studies included Enterococci from poultry faecal samples;<sup>21</sup> *E. coli* and Enterococci from pig faecal samples;<sup>22</sup> *E. coli* and Enterococci from poultry carcass rinsates;<sup>23,24</sup> and *Campylobacter* from retail poultry.<sup>23</sup> While it is difficult to make direct comparisons of data from different studies due to different methodologies, comparison of the results from these studies with our results does not suggest a trend of increasing resistance among bacteria from animals in New Zealand.

Of these studies, the two most directly comparable with our results are those conducted by investigators at Massey University using *E. coli* and Enterococci obtained from NMD programme poultry rinsate samples in 2006.<sup>23,24</sup> Among *E. coli* from poultry we found higher rates of streptomycin (10.1 vs 1.7%), sulphonamide (30.7 vs 0.7%) and tetracycline (12.1 vs 4.4%) resistance, but otherwise similar or lower rates of resistance. Some of the differences in streptomycin, sulphonamide and tetracycline resistance in *E. coli* could be due to methodology as disc testing was used in the Massey studies and the end point can be difficult to determine for these antibiotics. Among Enterococci from poultry, we found higher tetracycline resistance in *E. faecalis* (77.9 vs 48.2%) and higher quinupristin/dalfopristin resistance (31.7 vs 13.8%) in *E. faecium*, but otherwise lower rates of resistance.

Of particular note, vancomycin resistance in enterococci appears to have diminished substantially. A 2001 study in the Dunedin area, just a year after the withdrawal of the use of avoparcin in the rearing of broiler poultry in this country, found a high prevalence (16.0%) of vanA-type vancomycin resistance among mainly *E. faecalis*, but also *E. faecium*, from poultry faecal samples.<sup>21</sup> In contrast, the Massey study in 2006 identified only one of 401 poultry carcass enterococcal isolates was vancomycin resistant.<sup>23</sup> In this survey no vancomycin-resistant enterococci were recovered from any of the animal groups.

#### *Comparison of resistance with that found among animal bacterial isolates in other countries*

The methodology used in the survey was modeled on the DANMAP system for the surveillance of antimicrobial resistance in bacteria from food animals.<sup>11</sup> Therefore, DANMAP resistance data is likely to provide the most valid data on which we can make an international comparison. However, the animal groups included in the DANMAP system do not specifically include the category of very young calves, but do include pigs and broiler poultry. Also, in the DANMAP system, the MICs are interpreted mainly according to the European EUCAST epidemiological cut-off values, whereas CLSI's clinical breakpoints were mainly used to interpret the MICs obtained in this survey. Clinical breakpoints for MICs tend to be higher than epidemiological cut-off values, and therefore result in lower rates of resistance. While our use of clinical breakpoints allows the results from this survey to be more easily compared with resistance among human isolates in New Zealand, it makes it more difficult to compare the results with data on resistance among animal isolates in some other countries, especially those in Europe where epidemiological cut-off values are standardly used to interpret MICs.

After allowing for differences in interpretations of MICs and taking 95% confidence intervals into account, a comparison of 2009 DANMAP data with the results from this survey showed that, with the exception of higher resistance to sulphonamides in *E. coli* from poultry (30.7 vs 13.8%), resistance was either lower in New Zealand or not significantly different for the

antibiotics that were commonly tested in this survey and reported in the 2009 DANMAP report.

Among isolates from poultry, *C. jejuni* isolated in New Zealand were less resistant than Danish isolates to ciprofloxacin (2.7 vs 13.3%), nalidixic acid (2.7 vs 13.3%) and tetracycline (0.3 vs 12.0%). *E. coli* from New Zealand poultry were less resistant to ampicillin (4.9 vs 18.4%), and there were no significant differences in resistance among Enterococci from New Zealand poultry compared with Danish poultry.

Among isolates from pigs, *E. coli* isolated in New Zealand were less resistant than Danish isolates to ampicillin (8.9 vs 26.0%) and trimethoprim (8.3 vs 18.7%). *E. faecalis* from New Zealand pigs were less resistant to chloramphenicol (8.3 vs 20.3%), erythromycin (27.6 vs 48.9%), high-level streptomycin (21.1 vs 36.8%) and tetracycline (43.0 vs 88.0%), and *E. faecium* from New Zealand pigs were less resistant to high-level streptomycin (15.8 vs 37.7%) and tetracycline (38.6 vs 66.2%).

The results from this survey were also compared with 2008 data from the NARMS surveillance of antimicrobial resistance among retail meats in the United States.<sup>25</sup> The methods used for the NARMS surveillance system are similar to those used for this survey, and the MICs are interpreted according to CLSI clinical breakpoints. However, the NARMS system monitors resistance among bacteria isolated from retail meats: chicken breast, ground turkey, ground beef and pork chop.

Compared with retail chicken breast meat in the United States in 2008, and taking 95% confidence intervals into account, *C. jejuni* from New Zealand poultry were less resistant to ciprofloxacin (2.7 vs 14.6%), nalidixic acid (2.7 vs 14.6%) and tetracycline (0.3 vs 49.9%). *E. coli* from New Zealand poultry were less resistant to ampicillin (4.9 vs 23.5%), cefotaxime/ceftriaxone (0.0 vs 11.1%), cefoxitin (0.3 vs 11.8%), ceftiofur (0.0 vs 10.8%), co-amoxiclav (0.0 vs 11.8%), gentamicin (0.0 vs 34.0%) and tetracycline (12.1 vs 43.8%). *E. faecalis* from New Zealand poultry were less resistant to high-level gentamicin (0.0 vs 17.7%), and *E. faecium* were less resistant to high-level gentamicin (0.0 vs 8.6%), nitrofurantoin (29.8 vs 46.3%), quinupristin/dalfopristin (31.7 vs 54.9%) and tetracycline (35.4 vs 64.3%).

Compared with retail pork chop meat in the United States in 2008, *E. coli* from New Zealand pigs were more resistant to sulphonamides (32.7 vs 16.4%). *E. faecalis* from New Zealand pigs were more resistant to chloramphenicol (8.3 vs 0.4%), erythromycin (27.6 vs 8.3%), high-level gentamicin (8.3 vs 0.4%) and high-level streptomycin (21.1 vs 7.6%), but less resistant to tetracycline (43.0 vs 76.9%). There were no significant differences in resistance among *E. faecium* from New Zealand pigs compared with American pork chop.

Overall these results suggest that resistance among *Campylobacter*, *E. coli* and Enterococci from New Zealand poultry tended to be lower than that among these bacteria isolated from American retail chicken breast. Whereas, resistance among *E. faecalis* from New Zealand pigs was higher than that among this bacterial species isolated from American retail pork chop meat. However, resistance among *E. coli* and *E. faecium* from New Zealand pigs and American pork chop meat was similar.

This survey has provided useful baseline data on antimicrobial resistance among certain bacteria isolated from selected food animals and fresh produce. It had one major limitation that should be addressed in any such future surveys: the 12-month length of the survey was insufficient to provide adequate numbers of *Salmonella* from any of the animal groups or

*Campylobacter* from very young calves or pigs to accurately assess antimicrobial resistance among these groupings. On the other hand, the low numbers of these two pathogens is obviously desirable from a food safety point of view.

## 5 References

- 1 A review of the impact of the use of antimicrobials in animals and plants on the development of antimicrobial resistance in human bacterial pathogens. Report of the Expert Panel on Antibiotic Resistance. Wellington: New Zealand Food Safety Authority; July 2005. Available at [http://www.foodsafety.govt.nz/elibrary/industry/Review\\_Impact-Prepared\\_Appointed.pdf](http://www.foodsafety.govt.nz/elibrary/industry/Review_Impact-Prepared_Appointed.pdf) (last accessed 1 February 2011).
- 2 NZFSA response to Antimicrobial Resistance Expert Panel report and Steering Committee advice. Wellington: New Zealand Food Safety Authority; August 2006. Available at [http://www.foodsafety.govt.nz/elibrary/industry/Nzfsa\\_Response-Chemicals\\_Medicines.pdf](http://www.foodsafety.govt.nz/elibrary/industry/Nzfsa_Response-Chemicals_Medicines.pdf) (last accessed 1 February 2011).
- 3 McIntyre L, Cornelius A. Microbiological survey of retail fresh produce of imported domestic conventional and domestic organic origin. Christchurch: Institute of Environmental Science & Research Ltd; September 2009. Client Report No FW09064.
- 4 Wong TL, Devane ML, Hudson JA, et al. Validation of a PCR method for *Campylobacter* detection on poultry packs. *British Food J* 2004; 106: 642-50.
- 5 Kornacki JL, Johnson JL. Chapter 8: Enterobacteriaceae, coliforms, and *Escherichia coli* as quality and safety indicators. In: Downes FP and Ito K, editors. *Compendium of methods for the microbiological examination of foods*. 4th ed. Washington DC: American Public Health Association; 2001. p. 69-82.
- 6 Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. *J Clin Microbiol* 1995; 33: 24-7. (Note: Addendum in *J Clin Microbiol* 1995; 33: 1434).
- 7 Clinical Laboratory Standards Institute. *Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard – eighth edition*. Wayne (PA): CLSI; 2009. M07-A8.
- 8 Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial susceptibility testing; twentieth informational supplement*. Wayne (PA): CLSI; 2010. M100-S20.
- 9 Clinical Laboratory Standards Institute. *Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline – second edition*. Wayne (PA): CLSI; 2010. M45-A2.
- 10 Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard – third edition*. Wayne (PA): CLSI; 2008. M31-A3.
- 11 DANMAP 2009 – Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. Denmark: Statens Serum Institut; Danish Veterinary and Food Administration; Danish Medicines Agency; National Veterinary Institute and National Food Institute, Technical University of Denmark; 2009. Available at [http://www.danmap.org/pdfFiles/Danmap\\_2009.pdf](http://www.danmap.org/pdfFiles/Danmap_2009.pdf).

- 12 Yagi T, Wachino J, Kurokawa H, et al. Practical methods using boronic acid compounds for identification of class C  $\beta$ -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli*. J Clin Microbiol 2005; 43: 2551-8.
- 13 Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-62.
- 14 Clark NC, Cooksey RC, Hill BC, et al. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 1993; 37: 2311-7.
- 15 New Zealand Food Safety Authority. Antibiotic sales 2004-2009. Wellington: NZFSA; 2011.
- 16 Institute of Environmental Science and Research. Antimicrobial resistance data from hospital and community laboratories, 2009. Porirua: ESR; 2010. Available at [http://www.surv.esr.cri.nz/antimicrobial/general\\_antimicrobial\\_susceptibility.php](http://www.surv.esr.cri.nz/antimicrobial/general_antimicrobial_susceptibility.php) (last accessed 27 April 2011).
- 17 Institute of Environmental Science and Research. Antimicrobial susceptibility of *Salmonella*, 2009. Porirua: ESR; 2010. Available at [http://www.surv.esr.cri.nz/PDF\\_surveillance/Antimicrobial/SAL/SAL\\_2009.pdf](http://www.surv.esr.cri.nz/PDF_surveillance/Antimicrobial/SAL/SAL_2009.pdf) (last accessed 27 April 2011).
- 18 Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in *Escherichia coli* and *Salmonella*: recent developments. Int J Antimicrob Agents 2005; 25: 358-73.
- 19 Bax R, Bywater R, Cornaglia G, et al. Surveillance of antimicrobial resistance – what, how and wither? Clin Microbiol Infect 2001; 7: 316-25.
- 20 Richards DA, Toop LJ, Chambers ST, et al. Antibiotic resistance in uncomplicated urinary tract infections: problems with interpreting cumulative resistance rates from local community laboratories. NZ Med J 2002; 115: 12-4.
- 21 Manson JM, Keis S, Smith JMB, et al. A clonal lineage of vanA-type *E. faecalis* predominates in vancomycin-resistant enterococci isolated in New Zealand. Antimicrobial Agents Chemother 2003; 47: 204-10.
- 22 Nulsen MF, Mor MB, Lawton DEB. Antibiotic resistance among indicator bacteria isolated from healthy pigs in New Zealand. NZ Vet J 2008; 56: 29-35.
- 23 Pleydell E, Rogers L, Kwan E, et al. Low levels of antibacterial drug resistance expressed by Gram-negative bacteria isolated from poultry carcasses in New Zealand. NZ Vet J 2010; 58: 229-36.
- 24 Pleydell E, Rogers L, Kwan E, et al. Evidence for the clustering of antibacterial resistance phenotypes of enterococci within integrated poultry companies. Microb Ecol 2010; 59: 678-88.
- 25 US Food and Drug Administration and Centers for Disease Control. NARMS Retail meat annual report, 2008. Available at <http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/ucm237109.htm> (last accessed 25 April 2011).

## Appendices

Table 5. Range of antimicrobials to be tested for each bacterial group, as recommended by the *NZFSA Working Group on Implementation of Antimicrobial Resistance Surveillance*

	<i>E. coli</i>	<i>Salmonella</i>	<i>Enterococcus</i> <sup>1</sup>	<i>Campylobacter</i>
ampicillin/amoxicillin	√	√	√	
amoxicillin/clavulanate	√	√		
bacitracin zinc			√	
3 <sup>rd</sup> gen cephalosporins <sup>2</sup>	√	√		
chloramphenicol	√	√		
ciprofloxacin	√	√	√	√
erythromycin				√
gentamicin	√	√	√ <sup>3</sup>	√
nalidixic acid	√	√		√
nitrofurantoin			√	
quinu/dalfopristin <sup>4</sup>			√	
spectinomycin	√	√		
streptomycin	√	√	√ <sup>3</sup>	
sulphonamide	√	√		
tetracycline	√	√	√	√
trimethoprim	√	√		
tylosin			√	
vancomycin			√	

Notes

<sup>1</sup> *E. faecalis* and *E. faecium* only

<sup>2</sup> To include screening for extended-spectrum  $\beta$ -lactamases (ESBLs) and confirmation of any screen-positive isolates

<sup>3</sup> High-level resistance only

<sup>4</sup> *E. faecium* only

Table 6. Sensititre plate formats

Plate Code: **EUCAMP<sup>1</sup>**

	1	2	3	4	5	6	7	8	9	10	11	12
<b>A</b>	GM 16	SM 1	SM 2	SM 4	SM 8	SM 16	GM 16	SM 1	SM 2	SM 4	SM 8	SM 16
<b>B</b>	GM 8	CIP 4	TE 16	EM 32	NX 64	CM 32	GM 8	CIP 4	TE 16	EM 32	NX 64	CM 32
<b>C</b>	GM 4	CIP 2	TE 8	EM 16	NX 32	CM 16	GM 4	CIP 2	TE 8	EM 16	NX 32	CM 16
<b>D</b>	GM 2	CIP 1	TE 4	EM 8	NX 16	CM 8	GM 2	CIP 1	TE 4	EM 8	NX 16	CM 8
<b>E</b>	GM 1	CIP 0.5	TE 2	EM 4	NX 8	CM 4	GM 1	CIP 0.5	TE 2	EM 4	NX 8	CM 4
<b>F</b>	GM 0.5	CIP 0.25	TE 1	EM 2	NX 4	CM 2	GM 0.5	CIP 0.25	TE 1	EM 2	NX 4	CM 2
<b>G</b>	GM 0.25	CIP 0.12	TE 0.5	EM 1	NX 2	POS CON	GM 0.25	CIP 0.12	TE 0.5	EM 1	NX 2	POS CON
<b>H</b>	GM 0.12	CIP 0.06	TE 0.25	EM 0.5	POS CON	POS CON	GM 0.12	CIP 0.06	TE 0.25	EM 0.5	POS CON	POS CON

<sup>1</sup> Note: plate accommodates two test isolates

Code	Antimicrobial	Concentration range (mg/L)
GM	Gentamicin	0.12-16
SM	Streptomycin	1-16
CIP	Ciprofloxacin	0.06-4
TE	Tetracycline	0.25-16
EM	Erythromycin	0.5-32
NX	Nalidixic acid	2-64
CM	Chloramphenicol	2-32
POS CON	Positive control	

Plate Code: **NZFSAN**

	1	2	3	4	5	6	7	8	9	10	11	12
<b>A</b>	CTAX 0.25	CTAX 0.5	CTAX 1	CTAX 2	CTAX 4	CTAX 8	CTAX 16	CTAX 32	CP 4	CP 8	CP 16	CP 32
<b>B</b>	CIP 0.03	CIP 0.06	CIP 0.12	CIP 0.25	CIP 0.5	CIP 1	CIP 2	CIP 4	APR 4	APR 8	APR 16	APR 32
<b>C</b>	CFOX 0.5	CFOX 1	CFOX 2	CFOX 4	CFOX 8	CFOX 16	CFOX 32	CFUR 0.5	CFUR 1	CFUR 2	CFUR 4	CFUR 8
<b>D</b>	GM 1	GM 2	GM 4	GM 8	GM 16	GM 32	NX 2	NX 4	NX 8	NX 16	NX 32	NX 64
<b>E</b>	AMP 1	AMP 2	AMP 4	AMP 8	AMP 16	AMP 32	SFM 64	SFM 128	SFM 256	SFM 512	SFM 1024	CTAZ 1
<b>F</b>	SP 16	SP 32	SP 64	SP 128	SP 256	SM 4	SM 8	SM 16	SM 32	SM 64	TM 4	TM 32
<b>G</b>	AMC 2	AMC 4	AMC 8	AMC 16	AMC 32	TE 2	TE 4	TE 8	TE 16	TE 32	TM 8	POS CON
<b>H</b>	CM 4	CM 8	CM 16	CM 32	CM 64	NE 2	NE 4	NE 8	NE 16	NE 32	TM 16	POS CON

Code	Antimicrobial	Concentration range (mg/L)
CTAX	Cefotaxime	0.25-32
CP	Cephalothin	4-32
CIP	Ciprofloxacin	0.03-4
APR	Apramycin	2-32
CFOX	Cefoxitin	0.5-32
CFUR	Ceftiofur	0.5-8
GM	Gentamicin	1-32
NX	Nalidixic acid	2-64
AMP	Ampicillin	1-32
SFM	Sulfamethoxazole	64-1024
CTAZ	Ceftazidime	1
SP	Spectinomycin	16-256
SM	Streptomycin	4-64
TM	Trimethoprim	4-32
AMC	Amoxicillin/clavulanic acid, 2:1 ratio (Co-amoxiclav)	2-32 <sup>1</sup>
TE	Tetracycline	2-32
CM	Chloramphenicol	4-64
NE	Neomycin	2-32
POS CON	Positive control	

1 Refers to the amoxicillin concentration

Plate Code: **NZFSAP**

	1	2	3	4	5	6	7	8	9	10	11	12
<b>A</b>	GM 128	BAC 2	TYL 0.25	EM 1	TE 0.5	CIP 0.5	VM 0.5	QD 0.5	AMP 0.5	CM 2	NI 2	SM 128
<b>B</b>	GM 256	BAC 4	TYL 0.5	EM 2	TE 1	CIP 1	VM 1	QD 1	AMP 1	CM 4	NI 4	SM 256
<b>C</b>	GM 512	BAC 8	TYL 1	EM 4	TE 2	CIP 2	VM 2	QD 2	AMP 2	CM 8	NI 8	SM 512
<b>D</b>	GM 1024	BAC 16	TYL 2	EM 8	TE 4	CIP 4	VM 4	QD 4	AMP 4	CM 16	NI 16	SM 1024
<b>E</b>	GM 2048	BAC 32	TYL 4	EM 16	TE 8	CIP 8	VM 8	QD 8	AMP 8	CM 32	NI 32	SM 2048
<b>F</b>		BAC 64	TYL 8	EM 32	TE 16	CIP 16	VM 16	QD 16	AMP 16	CM 64	NI 64	POS CON
<b>G</b>		BAC 128	TYL 16	EM 64	TE 32	CIP 32	VM 32	QD 32	AMP 32			POS CON
<b>H</b>		BAC 256	TYL 32	EM 128	TE 64	TE 128	VM 64	VM 128				POS CON

Code	Antimicrobial	Concentration range (mg/L)
GM	Gentamicin	128-2048
BAC	Bacitracin	2-256
TYL	Tylosin tartrate	0.25-32
EM	Erythromycin	1-128
TE	Tetracycline	0.5-128
CIP	Ciprofloxacin	0.5-32
VM	Vancomycin	0.5-128
QD	Quinupristin/dalfopristin	0.5-32
AMP	Ampicillin	0.5-32
CM	Chloramphenicol	2-64
NI	Nitrofurantoin	2-64
SM	Streptomycin	128-2048
POS CON	Positive control	

Table 7. Interpretation of minimum inhibitory concentrations

	Minimum inhibitory concentration as mg/L (reference for interpretation) <sup>1</sup>								
	<i>Campylobacter</i>			<i>Salmonella</i> and <i>E. coli</i>			Enterococci		
	S <sup>2</sup>	I <sup>2</sup>	R <sup>2</sup>	S	I	R	S	I	R
Ampicillin				≤8	16	≥32 (8)	≤8	-	≥16 (8)
Apramycin				≤16	-	≥32(11)			
Cefotaxime				≤1	2	≥4 (8)			
Cefoxitin				≤8	16	≥32 (8)			
Ceftazidime				≤4	8	≥16 (8)			
Ceftiofur				≤2	4	≥8 (10)			
Cephalothin				≤8	16	≥32 (8)			
Chloramphenicol	≤16	-	≥32 (11)	≤8	16	≥32 (8)	≤8	16	≥32 (8)
Ciprofloxacin	≤1	2	≥4 (9)	≤1	2	≥4 (8)	≤1	2	≥4 (8)
Co-amoxiclav <sup>3</sup>				≤8	16	≥32 (8)			
Erythromycin	≤8	16	≥32 (9)				≤0.5	1-4	≥8 (8)
Gentamicin	≤1/≤2	-	≥2/≥4 <sup>4</sup> (11)	≤4	8	≥16 (8)	≤512	-	≥1024 <sup>5</sup> (8)
Nalidixic acid	≤16/≤32	-	≥32/≥64 <sup>6</sup> (11)	≤16	-	≥32 (8)			
Neomycin				≤4/≤8	-	≥8/≥16 <sup>7</sup> (11)			
Nitrofurantoin							≤32	64	≥128 (8)
Quinupristin/dalfopristin							≤1	2	≥4 (8)
Spectinomycin				≤32	64	≥128(10)			
Streptomycin	≤2/≤4	-	≥4/≥8 <sup>8</sup> (11)	≤16	-	≥32 (11)	≤1024	-	≥2048 <sup>5</sup> (8)
Sulfamethoxazole				≤256	-	≥512 (8)			
Tetracycline	≤4	8	≥16 (9)	≤4	8	≥16 (8)	≤4	8	≥16 (8)
Trimethoprim				≤8	-	≥16 (8)			
Vancomycin							≤4	8-16	≥32 (8)

1 The numbers given in parentheses refer to references cited in the Reference section of this document.

2 S, susceptible; I, intermediate resistance; R, resistant.

3 The concentrations given refer to the amoxicillin component.

4 DANMAP's gentamicin epidemiological cut-off values for *C. jejuni* and *C. coli* differ: ≤1 and ≥2 mg/L for *C. jejuni* and ≤2 and ≥4 mg/L for *C. coli*.

5 High-level resistance

6 DANMAP's nalidixic acid epidemiological cut-off values for *C. jejuni* and *C. coli* differ: ≤16 and ≥32 mg/L for *C. jejuni* and ≤32 and ≥64 mg/L for *C. coli*.

7 DANMAP's neomycin epidemiological cut-off values for *Salmonella* and *E. coli* differ: ≤4 and ≥8 mg/L for *Salmonella* and ≤8 and ≥16 mg/L for *E. coli*.

8 DANMAP's streptomycin epidemiological cut-off values for *C. jejuni* and *C. coli* differ: ≤2 and ≥4 mg/L for *C. jejuni* and ≤4 and ≥8 mg/L for *C. coli*.

Table 8. Isolation of *Campylobacter* from swabs of very young calf carcasses, pigs and poultry each quarter of the survey period

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
<b>Very young calves</b>												
<b>North Island plants</b>												
1	6	W	2						55 / 0	0	55 / 0	0
2	40	W							60 / 1	1	60 / 1	1
3	12	W							50 / 0	0	50 / 0	0
4	30	W							35 / 0	0	35 / 0	0
5	15	W							55 / 0	0	55 / 0	0
6	10	W							60 / 0	0	60 / 0	0
7	30	W							55 / 3	3	55 / 3	3
8	30	W							60 / 0	0	60 / 0	0
9	16	W							40 / 1	1	40 / 1	1
10	16	W							60 / 6	6	60 / 6	6
11	8	W	20 / 0	0					50 / 3	3	70 / 3	3
<b>South Island plants</b>												
12	5	F	20 / 1	1					40 / 5	5	60 / 6	6
13	4	F	10 / 1	1					40 / 1	1	50 / 2	2
14	8	W	15 / 2	2					25 / 1	1	40 / 3	3
15	4	F							10 / 0	0	10 / 0	0

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
16	12	W	20 / 5	5					35 / 1	1	55 / 6	6
17	1	F							5 / 0	0	5 / 0	0
18	8	W	25 / 2	2					45 / 3	3	70 / 5	5
19	1	F	5 / 0	0					50 / 2	2	55 / 2	2
20	4	W	25 / 3	3					30 / 1	1	55 / 4	4
21	8	W							45 / 5	5	45 / 5	5
22	15	W	15 / 0	0					35 / 0	0	50 / 0	0
23	1	F	4 / 2	2					0 / 0	0	4 / 2	2
24	6	F	25 / 4	4					35 / 3	3	60 / 7	7
<b>Pigs</b>												
<b>North Island plants</b>												
25	58	W	50 / 0	0	65 / 1	1	60 / 0	0	65 / 0	0	240 / 1	1
26	6	F	7 / 0	0	4 / 0	0	5 / 0	0	4 / 0	0	20 / 0	0
27	28	W	50 / 4	4	60 / 1	1	70 / 0	0	65 / 1	1	245 / 6	6
28	34	W	55 / 0	0	65 / 0	0	60 / 0	0	60 / 0	0	240 / 0	0
29	18	W	40 / 0	0	50 / 3	3	50 / 0	0	60 / 0	0	200 / 3	3
<b>South Island plants</b>												
30	6	F	7 / 0	0	5 / 0	0	4 / 0	0	5 / 0	0	21 / 0	0

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
31	46	W	40 / 0	0	65 / 0	0	65 / 0	0	60 / 0	0	230 / 0	0
32	46	W	50 / 0	0	65 / 0	0	65 / 0	0	60 / 1	1	240 / 1	1
33	58	W	55 / 0	0	50 / 0	0	55 / 0	0	65 / 0	0	225 / 0	0
<b>Poultry</b>												
<b>North Island plants</b>												
34	35	W	19 / 19	10	21 / 19	9	22 / 22	11	19 / 19	8	81 / 79	38
35	53	W	15 / 15	15	18 / 15	14	20 / 20	14	17 / 16	13	70 / 66	56
36	88	W	13 / 13	13	23 / 23	23	20 / 20	19	21 / 19	19	77 / 75	74
37	55	W	12 / 12	12	19 / 19	15	28 / 28	15	21 / 20	14	80 / 79	56
38	1	Q	4 / 4	2	0 / 0	0	0 / 0	0	0 / 0	0	4 / 4	2
39	11	F	8 / 7	3	13 / 11	3	8 / 7	3	6 / 5	3	35 / 30	12
<b>South Island plants</b>												
40	9	F	7 / 6	4	13 / 11	3	14 / 11	5	10 / 8	1	44 / 36	13
41	1	Q	3 / 3	2	0 / 0	0	0 / 0	0	0 / 0	0	3 / 3	2
42	44	W	13 / 12	12	19 / 18	14	6 / 6	6	13 / 12	12	51 / 48	44
43	1	Q	0 / 0	0	0 / 0	0	0 / 0	0	0 / 0	0	0 / 0	0

1 W, weekly; F fortnightly; Q, Quarterly.

2 Shaded cells represent the out-of-season quarters for processing very young calves.

Table 9. Isolation of *Escherichia coli* from swabs of very young calf carcasses, pigs and poultry each quarter of the survey period

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
<b>Very young calves</b>												
<b>North Island plants</b>												
1	6	W	2						45 / 21	12	45 / 21	12
2	40	W							40 / 20	20	40 / 20	20
3	12	W							51 / 22	20	51 / 22	20
4	30	W							32 / 14	14	32 / 14	14
5	15	W							43 / 19	18	43 / 19	18
6	10	W							49 / 22	11	49 / 22	11
7	30	W							40 / 20	20	40 / 20	20
8	30	W							50 / 27	27	50 / 27	27
9	16	W							42 / 18	18	42 / 18	18
10	16	W							60 / 29	24	60 / 29	24
11	8	W	19 / 18	3					43 / 18	9	62 / 36	12
<b>South Island plants</b>												
12	5	F	18 / 18	2					40 / 18	9	58 / 36	11
13	4	F	10 / 10	2					39 / 16	7	49 / 26	9
14	8	W	14 / 14	3					24 / 10	5	38 / 24	8
15	4	F							7 / 4	3	7 / 4	3

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
16	12	W	20 / 18	5					36 / 16	10	56 / 34	15
17	1	F							5 / 2	2	5 / 2	2
18	8	W	23 / 21	4					43 / 18	9	66 / 39	13
19	1	F	5 / 5	1					0 / 0	0	5 / 5	1
20	4	W	21 / 21	2					28 / 10	5	49 / 31	7
21	8	W							36 / 18	9	36 / 18	9
22	15	W	13 / 13	6					37 / 16	10	50 / 29	16
23	1	F	18 / 15	1					18 / 0	0	36 / 15	1
24	6	F	24 / 22	2					35 / 14	7	59 / 36	9
<b>Pigs</b>												
<b>North Island plants</b>												
25	58	W	36 / 26	15	32 / 22	15	27 / 18	15	39 / 24	13	134 / 90	58
26	6	F	1 / 1	1	2 / 1	1	1 / 1	1	0 / 0	0	4 / 3	3
27	28	W	39 / 28	9	29 / 17	8	30 / 14	7	27 / 18	11	125 / 77	35
28	34	W	42 / 29	10	23 / 16	9	26 / 18	9	35 / 20	10	126 / 83	38
29	18	W	16 / 7	5	41 / 22	10	29 / 17	5	2 / 2	2	88 / 48	22
<b>South Island plants</b>												
30	6	F	20 / 14	4	4 / 3	2	4 / 1	1	4 / 4	3	32 / 22	10

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
31	46	W	6 / 5	5	12 / 8	8	12 / 7	7	13 / 13	13	43 / 33	33
32	46	W	10 / 10	10	14 / 13	13	20 / 19	13	15 / 13	10	59 / 55	46
33	58	W	22 / 19	15	16 / 9	9	29 / 25	21	20 / 17	13	87 / 70	58
<b>Poultry</b>												
<b>North Island plants</b>												
34	35	W	21 / 18	9	22 / 21	11	24 / 21	11	23 / 23	10	90 / 83	41
35	53	W	10 / 9	9	14 / 14	14	19 / 13	12	17 / 15	15	60 / 51	50
36	88	W	30 / 30	29	20 / 18	18	24 / 22	21	23 / 20	20	97 / 90	88
37	55	W	33 / 30	14	39 / 30	14	39 / 28	14	39 / 25	14	150 / 113	56
38	1	Q	3 / 3	1	0 / 0	0	0 / 0	0	0 / 0	0	3 / 3	1
39	11	F	23 / 22	3	24 / 21	4	21 / 14	4	24 / 16	3	92 / 73	14
<b>South Island plants</b>												
40	9	F	11 / 7	3	11 / 10	4	4 / 2	2	4 / 2	2	30 / 21	11
41	1	Q	1 / 1	1	0 / 0	0	0 / 0	0	0 / 0	0	1 / 1	1
42	44	W	27 / 23	11	14 / 13	11	24 / 18	11	22 / 12	11	87 / 66	44
43	1	Q	0 / 0	0	0 / 0	0	0 / 0	0	0 / 0	0	0 / 0	0

1 W, weekly; F fortnightly; Q, Quarterly.

2 Shaded cells represent the out-of-season quarters for processing very young calves.

Table 10. Isolation of Enterococci from swabs of very young calf carcasses, pigs and poultry each quarter of the survey period

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
<b>Very young calves</b>												
<b>North Island plants</b>												
1	6	W	2						55 / 20	12	55 / 20	12
2	40	W							55 / 20	14	55 / 20	14
3	12	W							50 / 33	16	50 / 33	16
4	30	W							35 / 20	15	35 / 20	15
5	15	W							55 / 25	14	55 / 25	14
6	10	W							60 / 46	16	60 / 46	16
7	30	W							55 / 21	16	55 / 21	16
8	30	W							55 / 23	18	55 / 23	18
9	16	W							40 / 22	11	40 / 22	11
10	16	W							60 / 31	25	60 / 31	25
11	8	W	20 / 9	4					50 / 34	21	70 / 43	25
<b>South Island plants</b>												
12	5	F	20 / 10	3					40 / 30	6	60 / 40	9
13	4	F	10 / 4	2					40 / 17	4	50 / 21	6
14	8	W	15 / 9	4					25 / 14	6	40 / 23	10

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
15	4	F							10 / 1	1	10 / 1	1
16	12	W	20 / 5	4					35 / 14	11	55 / 19	15
17	1	F							5 / 3	2	5 / 3	2
18	8	W	25 / 8	4					40 / 18	6	65 / 26	10
19	1	F	5 / 1	1					45 / 24	1	50 / 25	2
20	4	W	25 / 15	4					35 / 24	3	60 / 39	7
21	8	W							40 / 21	8	40 / 21	8
22	15	W	15 / 1	1					40 / 23	10	55 / 24	11
23	1	F	3 / 3	3					0 / 0	0	3 / 3	3
24	6	F	25 / 8	2					35 / 19	9	60 / 27	11
<b>Pigs</b>												
<b>North Island plants</b>												
25	58	W	50 / 15	14	60 / 22	18	60 / 12	8	65 / 17	16	235 / 66	56
26	6	F	5 / 2	2	3 / 1	0	5 / 1	1	2 / 1	0	15 / 5	3
27	28	W	50 / 21	14	60 / 23	17	70 / 17	13	65 / 14	14	245 / 75	58
28	34	W	55 / 24	17	60 / 11	6	60 / 17	15	60 / 4	3	235 / 56	41
29	18	W	40 / 23	18	50 / 17	15	50 / 17	11	50 / 0	0	190 / 57	44
<b>South Island plants</b>												
30	6	F	7 / 6	4	5 / 2	2	4 / 1	1	5 / 1	0	21 / 10	7
31	46	W	40 / 3	2	65 / 3	2	65 / 12	9	60 / 10	7	230 / 28	20
32	46	W	50 / 10	7	65 / 8	6	65 / 8	5	60 / 10	7	240 / 36	25

Plant	Target number of isolates for whole survey	Freq. of sampling <sup>1</sup>	Quarter 1		Quarter 2		Quarter 3		Quarter 4		Total	
			Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST	Samples received/ isolates recovered	Isolates selected for AST
33	58	W	55 / 11	9	50 / 10	7	55 / 17	7	65 / 10	8	225 / 48	31
<b>Poultry</b>												
<b>North Island plants</b>												
34	35	W	32 / 30	9	33 / 29	9	37 / 24	9	42 / 26	8	144 / 109	35
35	53	W	32 / 25	14	36 / 27	14	39 / 25	15	42 / 29	10	149 / 106	53
36	88	W	24 / 24	21	36 / 31	25	39 / 30	22	42 / 31	20	141 / 116	88
37	55	W	33 / 31	14	41 / 29	16	39 / 25	13	37 / 25	12	150 / 110	55
38	1	Q	9 / 9	1	0 / 0	0	0 / 0	0	0 / 0	0	9 / 9	1
39	11	F	20 / 18	3	24 / 15	3	21 / 10	3	24 / 11	2	89 / 54	11
<b>South Island plants</b>												
40	9	F	15 / 8	1	24 / 17	4	18 / 8	3	18 / 9	1	75 / 42	9
41	1	Q	3 / 3	1	0 / 0	0	0 / 0	0	0 / 0	0	3 / 3	1
42	44	W	30 / 24	11	21 / 16	11	30 / 18	11	27 / 19	11	108 / 77	44
43	1	Q	3 / 1	1	0 / 0	0	0 / 0	0	0 / 0	0	3 / 1	1

1 W, weekly; F fortnightly; Q, Quarterly.

2 Shaded cells represent the out-of-season quarters for processing very young calves.

Table 11. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among *Campylobacter jejuni* isolated from very young calves (n=49) and poultry (n=295)<sup>1</sup>

Antimicrobial	Source	%S <sup>2</sup>	%I <sup>2</sup>	%R <sup>2</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>3</sup>															
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024
Chloramphenicol	calves	100	-	0.0 (0.0-7.3)								95.9	4.1							
	poultry	100	-	0.0 (0.0-1.3)								99.3	0.7							
Ciprofloxacin	calves	100	0.0	0.0 (0.0-7.3)		42.9	51.0	6.1												
	poultry	97.3	0.0	2.7 (1.2-5.3)		64.4	31.2	0.3	1.4				2.7							
Erythromycin	calves	100	0.0	0.0 (0.0-7.3)					85.7	12.2		2.0								
	poultry	100	0.0	0.0 (0.0-1.3)					95.6	2.0	2.0	0.3								
Gentamicin	calves	100	-	0.0 (0.0-7.3)			10.2	42.9	46.9											
	poultry	100	-	0.0 (0.0-1.3)			8.1	52.9	36.6	2.4										
Nalidixic acid	calves	100	-	0.0 (0.0-7.3)							6.1	71.4	18.4	4.1						
	poultry	97.3	-	2.7 (1.2-5.3)							14.2	78.6	3.4	1.0		2.4	0.3			
Streptomycin	calves	91.8	-	8.2 (2.3-19.6)						71.4	20.4	2.0			6.1					
	poultry	99.0	-	1.0 (0.2-3.0)						90.5	8.5	1.0								
Tetracycline	calves	100	0.0	0.0 (0.0-7.3)			98.0		2.0											
	poultry	99.7	0.0	0.3 (0.0-1.9)			98.0	1.0	0.7						0.3					

1 No *C. jejuni* isolated from pigs.

2 S, susceptible; I, intermediate resistance; R, resistant.

3 The white fields represent the range of dilutions tested. MIC values less than or equal to the lowest concentration tested are presented as this lowest concentration. MIC values greater than the highest concentration tested are presented as the next highest concentration after the highest concentration tested. The vertical bars indicate the breakpoints between the susceptibility categories. For antibiotics where there are two vertical lines, the first line represents the breakpoint between susceptible and intermediate, and the second line represents the breakpoint between intermediate and resistant. For antibiotics where there is one vertical line, the line represents the breakpoint between susceptible and resistant.

**Table 12. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among *Campylobacter coli* isolated from very young calves (n=7), pigs (n=10) and poultry (n=2)**

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>															
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024
Chloramphenicol	calves	100	-	0.0 (0.0-41.0)																
	pigs	100	-	0.0 (0.0-30.8)								100								
	poultry	100	-	0.0 (0.0-84.2)								80.0	20.0							
Ciprofloxacin	calves	100	0.0	0.0 (0.0-41.0)																
	pigs	100	0.0	0.0 (0.0-30.8)		85.7	14.3													
	poultry	100	0.0	0.0 (0.0-84.2)		30.0	60.0	10.0												
Erythromycin	calves	100	0.0	0.0 (0.0-41.0)						85.7	14.3									
	pigs	80.0	0.0	20.0 (2.5-55.6)					20.0	50.0		10.0					20.0			
	poultry	100	0.0	0.0 (0.0-84.2)					100											
Gentamicin	calves	100	-	0.0 (0.0-41.0)					28.6	71.4										
	pigs	100	-	0.0 (0.0-30.8)					60.0	40.0										
	poultry	100	-	0.0 (0.0-84.2)					100											
Nalidixic acid	calves	100	-	0.0 (0.0-41.0)								85.7	14.3							
	pigs	100	-	0.0 (0.0-30.8)								60.0	40.0							
	poultry	100	-	0.0 (0.0-84.2)								100								
Streptomycin	calves	100	-	0.0 (0.0-41.0)							14.3	85.7								
	pigs	80	-	20.0 (2.5-55.6)							50.0	30.0			20.0					
	poultry	100	-	0.0 (0.0-84.2)						50.0	50.0									
Tetracycline	calves	100	0.0	0.0 (0.0-41.0)				100												
	pigs	70	0.0	30.0 (6.7-65.2)				70.0							30.0					
	poultry	100	0.0	0.0 (0.0-84.2)				100												

1 S, susceptible; I, intermediate resistance; R, resistant.

2 The white fields represent the range of dilutions tested. MIC values less than or equal to the lowest concentration tested are presented as this lowest concentration. MIC values greater than the highest concentration tested are presented as the next highest concentration after the highest concentration tested. The vertical bars indicate the breakpoints between the susceptibility categories. For antibiotics where there are two vertical lines, the first line represents the breakpoint between susceptible and intermediate, and the second line represents the breakpoint between intermediate and resistant. For antibiotics where there is one vertical line, the line represents the breakpoint between susceptible and resistant.

**Table 13. Resistance among *Campylobacter jejuni* from very young calves and poultry recovered from processing plants in the North Island versus the South Island<sup>1</sup>**

	Percent resistance and P value for any significant, P ≤0.05, differences between resistance in the North Island and that in the South Island within the animal group or total								
	Very young calves n=49			Poultry n=295			All animal groups n=344		
	North Island n=13	South Island n=36	P value	North Island n=236	South Island n=59	P value	North Island n=249	South Island n=95	P value
Chloramphenicol	0.0	0.0		0.0	0.0		0.0	0.0	
Ciprofloxacin	0.0	0.0		0.4	11.9	<0.0001	0.4	7.4	0.0001
Erythromycin	0.0	0.0		0.0	0.0		0.0	0.0	
Gentamicin	0.0	0.0		0.0	0.0		0.0	0.0	
Nalidixic acid	0.0	0.0		0.4	11.9	<0.0001	0.4	7.4	0.0001
Streptomycin	7.7	8.3		0.9	1.7		1.2	4.2	
Tetracycline	0.0	0.0		0.4	0.0		0.4	0.0	

<sup>1</sup> No *C. jejuni* isolated from pigs.

**Table 14. Resistance among *Campylobacter jejuni* from very young calves and poultry during each quarter of the survey period<sup>1,2,3</sup>**

	Percent resistance									
	Very young calves n=49		Poultry n=295				All animal groups n=344			
	Q1 n=18	Q4 n=31	Q1 n=73	Q2 n=81	Q3 n=72	Q4 n=69	Q1 n=91	Q2 n=81	Q3 n=72	Q4 n=100
Chloramphenicol	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Ciprofloxacin	0.0	0.0	0.0	0.0	2.8	8.7	0.0	0.0	2.8	6.0
Erythromycin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gentamicin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Nalidixic acid	0.0	0.0	0.0	0.0	2.8	8.7	0.0	0.0	2.8	6.0
Streptomycin	11.1	6.5	2.7	0.0	1.4	0.0	4.4	0.0	1.4	2.0
Tetracycline	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	1.0

1 No *C. jejuni* isolated from pigs.

2 Q1, 5 October-31 December 2009; Q2, 1 January-31 March 2010; Q3, 1 April-30 June 2010; Q4, 1 July-3 October 2010.

3 Shaded cells indicate where there was a significant ( $P \leq 0.05$ ) difference in resistance between the quarters.

Table 15. Serotypes among *Salmonella* isolated from very young calves, pigs, poultry and fresh produce

Serotype	Number (%) of isolates				
	Very young calves (n=19)	Pigs (n=6)	Poultry (n=3)	Fresh produce (n=2 <sup>1</sup> )	Total (n=30)
<i>S. Brandenburg</i>	9 (47.4)	3 (50.0)			12 (40.0)
<i>S. Derby</i>		1 (16.7)	2 (66.7)		3 (10.0)
<i>S. Infantis</i>			1 (33.3)		1 (3.3)
<i>S. London</i>		1 (16.7)			1 (3.3)
<i>S. Ruiru</i>	1 (5.3)				1 (3.3)
<i>S. Senftenberg</i>	1 (5.3)				1 (3.3)
<i>S. Typimurium</i>					
phage type 1	1 (5.3)				1 (3.3)
phage type 9	3 (15.8)				3 (10.0)
phage type 12a	1 (5.3)				1 (3.3)
phage type 101	2 (10.5)	1 (16.7)			3 (10.0)
phage type 156	1 (5.3)				1 (3.3)
RDNC-May06				2 (100)	2 (6.7)

Both from organic lettuce.

Table 16. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among *Salmonella* isolated from very young calves (n=19), pigs (n=6), poultry (n=3) and fresh produce (n=2)

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>														
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512
Ampicillin	calves	100	0.0	0.0 (0.0-17.6)						89.5	10.5								
	pigs	100	0.0	0.0 (0.0-45.9)						100									
	poultry	100	0.0	0.0 (0.0-70.8)						66.7	33.3								
	produce	100	0.0	0.0 (0.0-84.2)							100								
Apramycin	calves	100	-	0.0 (0.0-17.6)							94.7	5.3							
	pigs	100	-	0.0 (0.0-45.9)							100								
	poultry	100	-	0.0 (0.0-70.8)							100								
	produce	100	-	0.0 (0.0-84.2)							100								
Cefotaxime	calves	100	0.0	0.0 (0.0-17.6)				100											
	pigs	100	0.0	0.0 (0.0-45.9)				100											
	poultry	100	0.0	0.0 (0.0-70.8)				100											
	produce	100	0.0	0.0 (0.0-84.2)				100											
Cefoxitin	calves	100	0.0	0.0 (0.0-17.6)						89.5	10.5								
	pigs	100	0.0	0.0 (0.0-45.9)						83.3	16.7								
	poultry	100	0.0	0.0 (0.0-70.8)							100								
	produce	100	0.0	0.0 (0.0-84.2)						50.0	50.0								
Ceftazidime	calves	100	0.0	0.0 (0.0-17.6)					100										
	pigs	100	0.0	0.0 (0.0-45.9)					100										
	poultry	100	0.0	0.0 (0.0-70.8)					100										
	produce	100	0.0	0.0 (0.0-84.2)					100										
Ceftiofur	calves	100	0.0	0.0 (0.0-17.6)				26.3	73.7										
	pigs	100	0.0	0.0 (0.0-45.9)				16.7	83.3										
	poultry	100	0.0	0.0 (0.0-70.8)				33.3	66.7										
	produce	100	0.0	0.0 (0.0-84.2)					100										
Cephalothin	calves	100	0.0	0.0 (0.0-17.6)						100									
	pigs	100	0.0	0.0 (0.0-45.9)						100									
	poultry	100	0.0	0.0 (0.0-70.8)						100									
	produce	100	0.0	0.0 (0.0-84.2)						100									

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>															
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024
Chloramphenicol	calves	100	0.0	0.0 (0.0-17.6)										100						
	pigs	100	0.0	0.0 (0.0-45.9)										100						
	poultry	100	0.0	0.0 (0.0-70.8)										100						
	produce	100	0.0	0.0 (0.0-84.2)										100						
Ciprofloxacin	calves	100	0.0	0.0 (0.0-17.6)	100															
	pigs	100	0.0	0.0 (0.0-45.9)	100															
	poultry	100	0.0	0.0 (0.0-70.8)	100															
	produce	100	0.0	0.0 (0.0-84.2)	100															
Co-amoxiclav	calves	100	0.0	0.0 (0.0-17.6)							100									
	pigs	100	0.0	0.0 (0.0-45.9)							100									
	poultry	100	0.0	0.0 (0.0-70.8)							100									
	produce	100	0.0	0.0 (0.0-84.2)							100									
Gentamicin	calves	100	0.0	0.0 (0.0-17.6)						94.7	5.3									
	pigs	100	0.0	0.0 (0.0-45.8)						100										
	poultry	100	0.0	0.0 (0.0-70.8)						100										
	produce	100	0.0	0.0 (0.0-84.2)						100										
Nalidixic acid	calves	100	-	0.0 (0.0-17.6)							5.3	84.2	10.5							
	pigs	100	-	0.0 (0.0-45.9)								100								
	poultry	100	-	0.0 (0.0-70.8)								100								
	produce	100	-	0.0 (0.0-84.2)								100								
Neomycin	calves	100	-	0.0 (0.0-17.6)							100									
	pigs	100	-	0.0 (0.0-45.9)							100									
	poultry	100	-	0.0 (0.0-70.8)							100									
	produce	100	-	0.0 (0.0-84.2)							100									
Spectinomycin	calves	63.2	36.8	0.0 (0.0-17.6)											63.2	36.8				
	pigs	66.7	33.3	0.0 (0.0-45.9)											66.7	33.3				
	poultry	66.7	33.3	0.0 (0.0-70.8)											66.7	33.3				
	produce	50.0	50.0	0.0 (0.0-84.2)											50.0	50.0				
Streptomycin	calves	89.5	-	10.5 (1.3-33.1)									42.1	47.4	10.5					
	pigs	100	-	0.0 (0.0-45.9)								33.3	50.0	16.7						
	poultry	100	-	0.0 (0.0-70.8)									100							
	produce	100	-	0.0 (0.0-84.2)										100						

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>															
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024
Sulfamethoxazole	calves	100	-	0.0 (0.0-17.6)												36.8	63.2			
	pigs	66.7	-	33.3 (4.3-77.7)												50.0	16.7			33.3
	poultry	100	-	0.0 (0.0-70.8)												33.3		66.7		
	produce	100	-	0.0 (0.0-84.2)													50.0	50.0		
Tetracycline	calves	100	0.0	0.0 (0.0-17.6)							100									
	pigs	100	0.0	0.0 (0.0-45.9)							100									
	poultry	100	0.0	0.0 (0.0-70.8)							100									
	produce	100	0.0	0.0 (0.0-84.2)							100									
Trimethoprim	calves	100	-	0.0 (0.0-17.6)								100								
	pigs	83.3	-	16.7 (0.4-64.1)								83.3					16.7			
	poultry	100	-	0.0 (0.0-70.8)								100								
	produce	100	-	0.0 (0.0-84.2)								100								

1 S, susceptible; I, intermediate resistance; R, resistant.

2 The white fields represent the range of dilutions tested. MIC values less than or equal to the lowest concentration tested are presented as this lowest concentration. MIC values greater than the highest concentration tested are presented as the next highest concentration after the highest concentration tested. The vertical bars indicate the breakpoints between the susceptibility categories. For antibiotics where there are two vertical lines, the first line represents the breakpoint between susceptible and intermediate, and the second line represents the breakpoint between intermediate and resistant. For antibiotics where there is one vertical line, the line represents the breakpoint between susceptible and resistant

Table 17. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among *Escherichia coli* isolated from very young calves (n=300), pigs (n=303), poultry (n=306) and fresh produce (n=90)

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>															
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024
Ampicillin	calves	76.0	0.3	23.7 (19.0-28.9)						2.0	38.3	34.7	1.0	0.3		23.7				
	pigs	89.8	1.3	8.9 (6.0-12.7)						8.3	46.9	33.0	1.7	1.3		8.9				
	poultry	95.1	0.0	4.9 (2.8-8.0)						12.4	55.6	25.2	2.0		0.3	4.6				
	produce	95.6	2.2	2.2 (0.3-7.8)						5.6	38.9	50.0	1.1	2.2	1.1	1.1				
Apramycin	calves	100	-	0.0 (0.0-1.2)								93.7	6.0	0.3						
	pigs	99.7	-	0.3 (0.0-1.8)								92.4	6.6	0.7	0.3					
	poultry	99.7	-	0.3 (0.0-1.8)								91.8	7.5	0.3		0.3				
	produce	100	-	0.0 (0.0-4.0)								94.4	4.4	1.1						
Cefotaxime	calves	99.3	0.7	0.0 (0.0-1.2)				97.7	1.0	0.7	0.7									
	pigs	99.7	0.3	0.0 (0.0-1.2)				99.7			0.3									
	poultry	100	0.0	0.0 (0.0-1.2)				100												
	produce	100	0.0	0.0 (0.0-4.0)				100												
Cefoxitin	calves	98.3	0.7	1.0 (0.2-2.9)						0.3	28.3	62.3	7.3	0.7	1.0					
	pigs	98.0	0.7	1.3 (0.4-3.3)						1.0	32.7	55.5	8.9	0.7	0.7	0.7				
	poultry	99.7	0.0	0.3 (0.0-1.8)				0.3	5.6	35.0	45.8	13.1		0.3						
	produce	97.8	0.0	2.2 (0.3-7.8)						16.7	65.6	15.6			2.2					
Ceftazidime	calves	NI <sup>3</sup>	NI	NI						98.3	1.7									
	pigs	NI	NI	NI						99.7	0.3									
	poultry	NI	NI	NI						99.7	0.3									
	produce	NI	NI	NI						98.9	1.1									
Ceftiofur	calves	100	0.0	0.0 (0.0-1.2)				98.0	2.0											
	pigs	100	0.0	0.0 (0.0-1.2)				98.4	1.3	0.3										
	poultry	100	0.0	0.0 (0.0-1.2)				99.7	0.3											
	produce	100	0.0	0.0 (0.0-4.0)				98.9	1.1											
Cephalothin	calves	74.7	21.3	4.0 (2.1-6.9)							24.7	50.0	21.3	2.3	1.7					
	pigs	80.5	17.5	2.0 (0.7-4.3)							42.6	38.0	17.5	1.3	0.7					
	poultry	86.3	11.8	2.0 (0.7-4.2)							50.7	35.6	11.8	2.0						
	produce	87.8	10.0	2.2 (0.3-7.8)							36.7	51.1	10.0		2.2					



Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% Cis)	Percent of isolates with an MIC of: <sup>2</sup>																	
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024	2048	
Sulfamethoxazole	calves	55.0	-	45.0 (39.3-50.8)												54.3		0.7		0.3	0.3	44.3
	pigs	67.3	-	32.7 (27.4-38.3)												65.0	0.7	1.7		1.0	0.3	31.4
	poultry	69.3	-	30.7 (25.6-36.2)												68.6	0.7			0.3	0.3	30.1
	produce	98.9	-	1.1 (0.0-6.0)												98.9						1.1
Tetracycline	calves	58.7	0.7	40.7 (35.1-46.5)							57.0	1.7	0.7		1.0	39.7						
	pigs	49.8	1.7	48.5 (42.8-54.3)							48.2	1.7	1.7	0.3	3.0	45.2						
	poultry	87.6	0.3	12.1(8.7-16.3)							85.0	2.6	0.3	1.3	2.3	8.5						
	produce	93.3	0.0	6.7 (2.5-13.9)							92.2	1.1		1.1		5.6						
Trimethoprim	calves	87.3	-	12.7 (9.1-17.0)								86.7	0.7	0.3		12.3						
	pigs	91.8	-	8.3 (5.4-11.9)								91.4	0.3	0.7		7.6						
	poultry	93.1	-	6.9 (4.3-10.3)								93.1				6.9						
	produce	98.9	-	1.1 (0.0-6.0)								98.9				1.1						

1 S, susceptible; I, intermediate resistance; R, resistant.

2 The white fields represent the range of dilutions tested. MIC values less than or equal to the lowest concentration tested are presented as this lowest concentration. MIC values greater than the highest concentration tested are presented as the next highest concentration after the highest concentration tested. The vertical bars indicate the breakpoints between the susceptibility categories. For antibiotics where there are two vertical lines, the first line represents the breakpoint between susceptible and intermediate, and the second line represents the breakpoint between intermediate and resistant. For antibiotics where there is one vertical line, the line represents the breakpoint between susceptible and resistant.

3 NI, not interpretable as ceftazidime only tested at the ESBL screening concentration of 1 mg/L which is below the breakpoint between susceptible and intermediate, therefore the susceptibility categories cannot be calculated.

Table 18. Resistance among *Escherichia coli* from very young calves, pigs and poultry recovered from processing plants in the North Island versus the South Island

	Percent resistance and P value for any significant, $P \leq 0.05$ , differences between resistance in the North Island and that in the South Island within the animal group or total											
	Very young calves n=300			Pigs n=303			Poultry n=306			All animal groups n=909		
	North Island n=196	South Island n=104	P value	North Island n=156	South Island n=147	P value	North Island n=250	South Island n=56	P value	North Island n=602	South Island n=307	P value
Ampicillin	20.9	28.9		11.5	6.1		4.8	5.4		11.8	13.7	
Apramycin	0.0	0.0		0.6	0.0		0.4	0.0		0.3	0.0	
Cefotaxime	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	
Cefoxitin	1.0	1.0		0.6	2.0		0.0	1.8	0.0343	0.5	1.6	
Ceftiofur	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	
Cephalothin	4.1	3.9		1.9	2.0		2.0	1.8		2.7	2.6	
Chloramphenicol	4.1	1.9		14.7	5.4	0.0076	0.4	1.8		5.3	3.6	
Ciprofloxacin	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	
Co-amoxiclav	1.0	1.0		0.6	0.7		0.0	0.0		0.5	0.7	
Gentamicin	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	
Nalidixic acid	0.5	0.0		0.6	0.7		5.6	5.4		2.7	1.3	
Neomycin	28.6	27.9		3.9	1.4		2.8	3.6		11.5	10.8	
Spectinomycin	8.2	9.6		30.1	18.4	0.0172	3.6	16.1	0.0003	12.0	15.0	
Streptomycin	45.4	42.3		39.7	24.5	0.0046	8.0	19.6	0.0091	28.4	29.6	
Sulfamethoxazole	45.4	44.2		39.1	25.9	0.0140	31.6	26.8		38.0	32.3	
Tetracycline	39.8	42.3		41.7	55.8	0.0140	12.4	10.7		28.9	43.0	<0.0001
Trimethoprim	12.8	12.5		9.0	7.5		4.0	19.6	<0.0001	8.1	11.4	

Table 19. Resistance among *Escherichia coli* from very young calves, pigs and poultry during each quarter of the survey period<sup>1,2</sup>

	Percent resistance													
	Very young calves n=300		Pigs n=303				Poultry n=306				All animal groups n=909			
	Q1 n=31	Q4 n=269	Q1 n=74	Q2 n=75	Q3 n=79	Q4 n=75	Q1 n=80	Q2 n=76	Q3 n=75	Q4 n=75	Q1 n=185	Q2 n=151	Q3 n=154	Q4 n=419
Ampicillin	38.7	21.9	4.1	13.3	11.4	6.7	6.3	4.0	4.0	5.3	10.8	8.6	7.8	16.2
Apramycin	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.5
Cefotaxime	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cefoxitin	0.0	1.1	2.7	0.0	1.3	1.3	0.0	0.0	1.3	0.0	1.1	0.0	1.3	1.0
Ceftiofur	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cephalothin	6.5	3.7	2.7	1.3	1.3	2.7	1.3	1.3	1.3	4.0	2.7	1.3	1.3	3.6
Chloramphenicol	0.0	3.7	13.5	6.7	8.9	12.0	0.0	0.0	1.3	1.3	5.4	3.3	5.2	4.8
Ciprofloxacin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Co-amoxiclav	0.0	1.1	0.0	0.0	1.3	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.0
Gentamicin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Nalidixic acid	0.0	0.4	1.4	1.3	0.0	0.0	3.8	5.3	4.0	9.3	2.2	3.3	2.0	1.9
Neomycin	45.2	26.4	1.4	2.7	0.0	6.7	3.8	2.6	1.3	4.0	9.7	2.7	0.7	18.9
Spectinomycin	3.2	9.3	23.0	21.3	22.8	30.7	6.3	5.3	9.3	2.7	12.4	13.3	16.2	11.9
Streptomycin	58.1	42.8	27.0	34.7	31.7	36.0	10.0	9.2	12.0	9.3	24.9	21.9	22.1	35.6
Sulfamethoxazole	58.1	43.5	28.4	29.3	29.1	44.0	33.8	27.6	34.7	26.7	35.7	28.5	31.8	40.6
Tetracycline	58.1	38.7	33.8	50.7	54.4	54.7	11.3	11.8	10.7	14.7	28.1	31.1	33.1	37.2
Trimethoprim	19.4	11.9	10.8	6.7	8.9	6.7	10.0	5.3	6.7	5.3	11.9	6.0	7.8	9.8

1 Q1, 5 October-31 December 2009; Q2, 1 January-31 March 2010; Q3, 1 April-30 June 2010; Q4, 1 July-3 October 2010.

2 Shaded cells indicate where there was a significant ( $P \leq 0.05$ ) difference in resistance between the quarters.

Table 20. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among *Enterococcus faecalis* isolated from very young calves (n=185), pigs (n=228) and poultry (n=140)

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>																
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024	2048
Ampicillin	calves	100	0.0	0.0 (0.0-2.0)					30.3	63.8	4.9	1.1									
	pigs	100	0.0	0.0 (0.0-1.6)					29.0	66.2	4.0	0.9									
	poultry	100	0.0	0.0 (0.0-2.6)					30.7	65.0	3.6	0.7									
Bacitracin <sup>3</sup>	calves	-	-	-									1.1	3.2	8.1	33.5	47.6	1.6	4.9		
	pigs	-	-	-							0.4			0.4	10.1	31.6	45.6	5.7	6.1		
	poultry	-	-	-											0.7	2.1	1.4	0.7	95.0		
Chloramphenicol	calves	86.5	9.7	3.8 (1.5-7.6)								2.7	83.8	9.7		3.2	0.5				
	pigs	85.5	6.1	8.3 (5.1-12.7)							0.4	8.3	76.8	6.1	0.4	5.3	2.6				
	poultry	95.0	5.0	0.0 (0.0-2.6)								10.0	85.0	5.0							
Ciprofloxacin	calves	77.3	21.1	1.6 (0.3-4.7)					8.1	69.2	21.1	1.6									
	pigs	83.8	15.4	0.9 (0.1-3.1)					22.8	61.0	15.4	0.4	0.4								
	poultry	81.4	17.9	0.7 (0.0-3.9)					15.7	65.7	17.9	0.7									
Erythromycin <sup>4</sup>	calves	-	-	11.4 (7.2-16.8)						80.5	6.5	1.6	1.1					10.3			
	pigs	-	-	27.6 (21.9-33.9)						61.0	11.0	0.4	0.9	0.9	0.4		0.4	25.0			
	poultry	-	-	33.6 (25.8-42.0)						55.0	10.0	1.4	10.7	2.9	0.7	0.7		18.6			
High-level Gentamicin	calves	100	-	0.0 (0.0-2.0)													100				
	pigs	91.7	-	8.3 (5.1-12.7)													89.5	2.2		8.3	
	poultry	100	-	0.0 (0.0-2.6)													100				
Nitrofurantoin	calves	80.0	18.9	1.1 (0.1-3.9)									6.0	52.4	21.6	18.9	1.1				
	pigs	92.5	7.0	0.4 (0.0-2.4)							0.4			12.3	74.6	5.3	7.0	0.4			
	poultry	93.6	5.0	1.4 (0.2-5.1)										11.4	72.1	10.0	5.0	1.4			
High-level Streptomycin	calves	64.3	-	35.7 (28.8-43.0)													61.1	1.1		2.2	35.7
	pigs	79.0	-	21.1 (15.9-26.9)													76.8	0.9	0.4	0.9	21.1
	poultry	96.4	-	3.6 (1.2-8.1)													91.4	4.3	0.7		3.6
Tetracycline	calves	43.8	1.6	54.6 (47.1-61.9)					13.5	28.1	1.1	1.1	1.6	2.7	24.9	22.2	4.9				
	pigs	56.6	0.4	43.0 (36.5-49.7)					39.9	14.9	1.3	0.4	0.4	1.8	4.4	18.9	18.0				
	poultry	22.1	0.0	77.9 (70.1-84.4)					15.0	7.1					10.0	22.9	45.0				

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>															
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024
Tylosin <sup>3</sup>	calves	-	-	-						6.0	79.5	2.2	0.5	0.5		11.4				
	pigs	-	-	-						10.5	58.8	1.8	0.9		0.4	27.6				
	poultry	-	-	-						3.6	61.4	0.7			0.7	33.6				
Vancomycin	calves	100	0.0	0.0 (0.0-2.0)					15.1	55.7	28.7	0.5								
	pigs	99.6	0.4	0.0 (0.0-1.6)					4.0	71.9	23.7									
	poultry	100	0.0	0.0 (0.0-2.6)					36.4	62.1	1.4									

1 S, susceptible; I, intermediate resistance; R, resistant.

2 The white fields represent the range of dilutions tested. MIC values less than or equal to the lowest concentration tested are presented as this lowest concentration. MIC values greater than the highest concentration tested are presented as the next highest concentration after the highest concentration tested. The vertical bars indicate the breakpoints between the susceptibility categories. For antibiotics where there are two vertical lines, the first line represents the breakpoint between susceptible and intermediate, and the second line represents the breakpoint between intermediate and resistant. For antibiotics where there is one vertical line, the line represents the breakpoint between susceptible and resistant.

3 There are no bacitracin or tylosin interpretive standards for Enterococci.

4 Erythromycin susceptible and intermediate isolates cannot be distinguished with the range of concentrations used.

Table 21. Prevalence of resistance, intermediate resistance and susceptibility, and distribution of minimum inhibitory concentrations (MICs), among *Enterococcus faecium* isolated from very young calves (n=92), pigs (n=57) and poultry (n=158)

Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup> (95% CIs)	Percent of isolates with an MIC of: <sup>2</sup>																
					0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024	2048
Ampicillin	calves	100	0.0	0.0 (0.0-3.9)					65.2	18.5	8.7	5.4	2.2								
	pigs	100	0.0	0.0 (0.0-6.3)					38.6	17.5	15.8	21.1	7.0								
	poultry	100	0.0	0.0 (0.0-2.3)					36.1	19.6	21.5	17.7	5.1								
Bacitracin <sup>3</sup>	calves	-	-	-									2.2	2.2	9.8	56.5	14.1	8.7	6.5		
	pigs	-	-	-									1.8	3.5	5.3	5.3	35.1	19.3	29.8		
	poultry	-	-	-											0.6		0.6		98.7		
Chloramphenicol	calves	98.9	1.1	0.0 (0.0-3.9)								12.0	87.0	1.1							
	pigs	93.0	5.3	1.8 (0.0-9.4)								40.4	52.6	5.3		1.8					
	poultry	89.2	10.1	0.6 (0.0-3.5)								22.8	66.5	10.1	0.6						
Ciprofloxacin	calves	9.8	10.9	79.4 (69.6-87.1)					2.2	7.6	10.9	79.4									
	pigs	42.1	24.6	33.3 (21.4-47.1)					14.1	28.1	24.6	26.3	7.0								
	poultry	26.6	27.9	45.6 (37.6-53.7)					4.4	22.2	27.9	41.8	3.8								
Erythromycin <sup>4</sup>	calves	-	-	9.8 (4.6-17.8)						79.4	7.6	3.3	1.1				1.1	7.6			
	pigs	-	-	24.6 (14.1-37.8)						57.9	14.0	3.5	7.0	3.5				14.0			
	poultry	-	-	24.7 (18.2-32.2)						69.6	3.2	2.5	0.6	0.6	1.9		1.3	20.3			
High-level Gentamicin	calves	100	-	0.0 (0.0-3.9)																100	
	pigs	100	-	0.0 (0.0-6.3)																100	
	poultry	100	-	0.0 (0.0-2.3)																100	
Nitrofurantoin	calves	18.5	71.7	9.8 (4.6-17.8)										7.6	10.9	71.7	9.8				
	pigs	10.5	68.4	21.1 (11.4-33.9)										1.8	8.8	68.4	21.1				
	poultry	33.5	36.7	29.8 (22.7-37.5)									0.6	3.8	29.1	36.7	29.8				
Quinupristin/ dalfopristin	calves	66.3	7.6	26.1 (17.5-36.3)					65.2	1.1	7.6	18.5	7.6								
	pigs	50.9	19.3	29.8 (18.4-43.4)					38.6	12.3	19.3	22.8	7.0								
	poultry	22.2	46.2	31.7 (24.5-39.5)					8.9	13.3	46.2	22.2	9.5								
High-level Streptomycin	calves	88.0	-	12.0 (6.1-20.4)													84.8	2.2		1.1	12.0
	pigs	84.2	-	15.8 (7.4-27.9)													82.5	1.8			15.8
	poultry	96.8	-	3.2 (1.0-7.2)													96.2	0.6			3.2
Tetracycline	calves	37.0	1.1	62.0 (51.2-71.9)					33.7	3.3			1.1	1.1	12.0	38.0	10.9				
	pigs	61.4	0.0	38.6 (26.0-52.4)					54.4	1.8	1.8	3.5		1.8	1.8	17.5	17.5				
	poultry	60.1	4.4	35.4 (28.0-43.4)					53.2	3.2	1.3	2.5	4.4	1.9	3.8	23.4	6.3				
Antimicrobial	Source	%S <sup>1</sup>	%I <sup>1</sup>	%R <sup>1</sup>	Percent of isolates with an MIC of: <sup>2</sup>																

		(95% CIs)			0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1024	2048
Tylosin <sup>3</sup>	calves	-	-	-					43.5	31.5	8.7	7.6			8.7						
	pigs	-	-	-					3.5	54.4	24.6	3.5			14.0						
	poultry	-	-	-					1.3	27.2	45.6	2.5			23.4						
Vancomycin	calves	100	0.0	0.0 (0.0-3.9)					76.1	12.0	12.0										
	pigs	98.3	1.8	0.0 (0.0-6.3)					66.7	12.3	17.5	1.8	1.8								
	poultry	100	0.0	0.0 (0.0-2.3)					63.9	26.0	10.1										

1 S, susceptible; I, intermediate resistance; R, resistant.

2 The white fields represent the range of dilutions tested. MIC values less than or equal to the lowest concentration tested are presented as this lowest concentration. MIC values greater than the highest concentration tested are presented as the next highest concentration after the highest concentration tested. The vertical bars indicate the breakpoints between the susceptibility categories. For antibiotics where there are two vertical lines, the first line represents the breakpoint between susceptible and intermediate, and the second line represents the breakpoint between intermediate and resistant. For antibiotics where there is one vertical line, the line represents the breakpoint between susceptible and resistant.

3 There are no bacitracin or tylosin interpretive standards for Enterococci.

4 Erythromycin susceptible and intermediate isolates cannot be distinguished with the range of concentrations used.

Table 22. Resistance among *Enterococcus faecalis* from very young calves, pigs and poultry recovered from processing plants in the North Island versus the South Island

	Percent resistance and P value for any significant, $P \leq 0.05$ , differences between resistance in the North Island and that in the South Island within the animal group or total											
	Very young calves n=185			Pigs n=228			Poultry n=140			All animal groups n=553		
	North Island n=126	South Island n=59	P value	North Island n=164	South Island n=64	P value	North Island n=112	South Island n=28	P value	North Island n=401	South Island n=151	P value
Ampicillin	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	
Chloramphenicol	3.2	5.1		9.8	4.7		0.0	0.0		5.0	4.0	
Ciprofloxacin	1.6	1.7		0.0	3.1		0.9	0.0		0.8	2.0	
Erythromycin	11.1	11.9		30.5	20.3		33.9	32.1		25.4	19.2	
High-level Gentamicin	0.0	0.0		11.0	1.6	0.0173	0.0	0.0		4.5	0.7	0.0282
Nitrofurantoin	1.6	0.0		0.6	0.0		1.8	0.0		1.2	0.0	
High-level Streptomycin	27.8	52.5	0.0010	23.2	15.6		4.5	0.0		19.4	27.2	0.0482
Tetracycline	52.4	59.3		34.2	65.6	<0.0001	76.8	82.1		51.7	66.2	0.0023
Vancomycin	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	

Table 23. Resistance among *Enterococcus faecium* from very young calves, pigs and poultry recovered from processing plants in the North Island versus the South Island

	Percent resistance and P value for any significant, $P \leq 0.05$ , differences between resistance in the North Island and that in the South Island within the animal group or total											
	Very young calves n=92			Pigs n=57			Poultry n=158			All animal groups n=307		
	North Island n=56	South Island n=36	P value	North Island n=38	South Island n=19	P value	North Island n=131	South Island n=27	P value	North Island n=225	South Island n=82	P value
Ampicillin	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	
Chloramphenicol	0.0	0.0		0.0	5.3		0.8	0.0		0.4	1.2	
Ciprofloxacin	80.4	77.8		18.4	63.2	0.0007	44.3	51.9		48.9	65.9	0.0084
Erythromycin	12.5	5.6		15.8	42.1	0.0487	24.4	25.9		20.0	20.7	
High-level Gentamicin	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	
Nitrofurantoin	14.3	2.8		18.4	26.3		31.3	22.2		24.9	14.6	
Quinupristin/ dalfopristin	33.9	13.9	0.0327	23.7	42.1		31.3	33.3		30.7	26.8	
High-level Streptomycin	12.5	11.1		10.5	26.3		3.8	0.0		7.1	11.0	
Tetracycline	67.9	52.8		29.0	57.9	0.0343	31.3	55.6	0.0164	40.0	54.9	0.0201
Vancomycin	0.0	0.0		0.0	0.0		0.0	0.0		0.0	0.0	

Table 24. Resistance among *Enterococcus faecalis* from very young calves, pigs and poultry during each quarter of the survey period<sup>1,2</sup>

	Percent resistance													
	Very young calves n=185		Pigs n=228				Poultry n=140				All animal groups n=553			
	Q1 n=19	Q4 n=166	Q1 n=75	Q2 n=54	Q3 n=57	Q4 n=42	Q1 n=41	Q2 n=32	Q3 n=38	Q4 n=29	Q1 n=135	Q2 n=86	Q3 n=95	Q4 n=237
Ampicillin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chloramphenicol	0.0	4.2	5.3	11.1	5.3	14.3	0.0	0.0	0.0	0.0	3.0	7.0	3.2	5.5
Ciprofloxacin	0.0	1.8	0.0	1.9	0.0	2.4	0.0	0.0	2.6	0.0	0.0	1.2	1.1	1.7
Erythromycin	21.1	10.2	22.7	24.1	35.1	31.0	26.8	21.9	39.5	48.3	23.7	23.3	36.8	18.6
High-level Gentamicin	0.0	0.0	6.7	7.4	12.3	7.1	0.0	0.0	0.0	0.0	3.7	4.7	7.4	1.3
Nitrofurantoin	0.0	1.2	0.0	1.9	0.0	0.0	0.0	0.0	2.6	3.5	0.0	1.2	1.1	1.3
High-level Streptomycin	57.9	33.1	20.0	22.2	26.3	14.3	0.0	0.0	7.9	6.9	19.3	14.0	19.0	26.6
Tetracycline	57.9	54.2	37.3	37.0	52.6	47.6	87.8	62.5	73.7	86.2	55.6	46.5	61.1	57.0
Vancomycin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

1 Q1, 5 October-31 December 2009; Q2, 1 January-31 March 2010; Q3, 1 April-30 June 2010; Q4, 1 July-3 October 2010.

2 Shaded cells indicate where there was a significant ( $P \leq 0.05$ ) difference in resistance between the quarters.

Table 25. Resistance among *Enterococcus faecium* from very young calves, pigs and poultry during each quarter of the survey period<sup>1,2</sup>

	Percent resistance													
	Very young calves n=92		Pigs n=57				Poultry n=158				All animal groups n=307			
	Q1 n=13	Q4 n=79	Q1 n=12	Q2 n=19	Q3 n=12	Q4 n=14	Q1 n=35	Q2 n=50	Q3 n=38	Q4 n=35	Q1 n=60	Q2 n=69	Q3 n=50	Q4 n=128
Ampicillin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chloramphenicol	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	2.6	0.0	0.0	0.0	2.0	0.8
Ciprofloxacin	84.6	78.5	25.0	36.8	25.0	42.9	51.4	46.0	42.1	42.9	53.3	43.5	38.0	64.8
Erythromycin	7.7	10.1	16.7	47.4	16.7	7.1	37.1	20.0	18.4	25.7	26.7	27.5	18.0	14.1
High-level Gentamicin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Nitrofurantoin	0.0	11.4	16.7	36.8	25.0	0.0	17.1	34.0	23.7	42.9	13.3	34.8	24.0	18.8
Quinupristin/ dalfopristin	15.4	27.9	16.7	52.6	25.0	14.3	37.1	34.0	29.0	25.7	28.3	39.1	28.0	25.8
High-level Streptomycin	15.4	11.4	0.0	31.6	8.3	14.3	5.7	4.0	2.6	0.0	6.7	11.6	4.0	8.6
Tetracycline	46.2	64.6	33.3	47.4	33.3	35.7	31.4	44.0	34.2	28.6	35.0	44.9	34.0	51.6
Vancomycin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

1 Q1, 5 October-31 December 2009; Q2, 1 January-31 March 2010; Q3, 1 April-30 June 2010; Q4, 1 July-3 October 2010.

2 Shaded cells indicate where there was a significant ( $P \leq 0.05$ ) difference in resistance between the quarters.

Table 26. Resistance among human isolates of *Campylobacter*, *Salmonella*, *Escherichia coli*, *Enterococcus faecalis* and *E. faecium*, 2009<sup>1</sup>

Antimicrobial	Percent resistance			
	<i>Campylobacter</i>	<i>Salmonella</i>	<i>E. coli</i> <sup>2</sup>	<i>E. faecalis</i> / <i>E. faecium</i>
Ampicillin		5.5	51.4	3.6
Cefotaxime			3.0	
Cephalothin		1.7 <sup>3</sup>	22.2	
Chloramphenicol		3.0		
Ciprofloxacin	1.6	0.9	7.7	
Co-amoxiclav		1.7	10.7	
Erythromycin	0.0			
Gentamicin		1.7	3.7	25.5 <sup>4</sup>
Nalidixic acid		3.8		
Nitrofurantoin				0.8
Streptomycin		5.1		
Sulphonamides		6.0		
Tetracycline		4.7		68.9
Trimethoprim		2.1	24.1	
Vancomycin				0.4


1 The *Campylobacter*, *E. coli* and Enterococci data is based on resistance data collected from diagnostic laboratories throughout New Zealand and is available at [http://www.surv.esr.cri.nz/antimicrobial/general\\_antimicrobial\\_susceptibility.php](http://www.surv.esr.cri.nz/antimicrobial/general_antimicrobial_susceptibility.php). The *Salmonella* data is based on isolates referred to ESR for serotyping, a random sample of which is susceptibility tested, and the results are available at <http://www.surv.esr.cri.nz/antimicrobial/salmonella.php>.

2 Data for urinary *E. coli*.

3 There were four cephalothin-resistant isolates and three produced extended-spectrum- $\beta$ -lactamase and one produced AmpC  $\beta$ -lactamase.


4 High-level gentamicin resistance.

Figure 1. Comparison of resistance among *Escherichia coli* from very young calves, pigs, poultry, 2009-2010, and urinary isolates from humans, 2009<sup>1</sup>



1 The human *E. coli* data is based on resistance data collected from diagnostic laboratories throughout New Zealand and is available at [http://www.surv.esr.cri.nz/antimicrobial/general\\_antimicrobial\\_susceptibility.php](http://www.surv.esr.cri.nz/antimicrobial/general_antimicrobial_susceptibility.php).

Figure 2. Comparison of resistance among *E. faecalis* from very young calves, pigs, poultry, 2009-2010, with *E. faecalis* and *E. faecium* isolates from humans, 2009<sup>1</sup>



The human *E. faecalis* and *E. faecium* data is based on resistance data collected from diagnostic laboratories throughout New Zealand and is available at [http://www.surv.esr.cri.nz/antimicrobial/general\\_antimicrobial\\_susceptibility.php](http://www.surv.esr.cri.nz/antimicrobial/general_antimicrobial_susceptibility.php). Separate data for only *E. faecalis* is not available, but 90% of human enterococcal infections are usually due to *E. faecalis*.